| Year |
Citation |
Score |
| 2023 |
Bonavida B. Historical Perspectives of the Role of NO/NO Donors in Anti-Tumor Activities: Acknowledging Dr. Keefer's Pioneering Research. Critical Reviews in Oncogenesis. 28: 1-13. PMID 37824383 DOI: 10.1615/CritRevOncog.2021035853 |
0.305 |
|
| 2023 |
Jung M, Bui I, Bonavida B. Role of YY1 in the Regulation of Anti-Apoptotic Gene Products in Drug-Resistant Cancer Cells. Cancers. 15. PMID 37686541 DOI: 10.3390/cancers15174267 |
0.401 |
|
| 2023 |
Bui I, Baritaki S, Libra M, Zaravinos A, Bonavida B. Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic Implications. Antioxidants & Redox Signaling. PMID 37466477 DOI: 10.1089/ars.2023.0250 |
0.361 |
|
| 2023 |
Moghaddam M, Vivarelli S, Falzone L, Libra M, Bonavida B. Cancer resistance via the downregulation of the tumor suppressors and expressions: therapeutic implications. Exploration of Targeted Anti-Tumor Therapy. 4: 170-207. PMID 37205308 DOI: 10.37349/etat.2023.00128 |
0.406 |
|
| 2022 |
Cessna H, Baritaki S, Zaravinos A, Bonavida B. The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment. Cancers. 14. PMID 36230521 DOI: 10.3390/cancers14194596 |
0.37 |
|
| 2022 |
Valafar B, Zaravinos A, Bonavida B. Cross Talk between the Circadian Clock Proteins and TP53 in Cancer and Therapeutic Significance. Critical Reviews in Oncogenesis. 26: 19-36. PMID 35381145 DOI: 10.1615/CritRevOncog.2022042860 |
0.301 |
|
| 2021 |
Navasardyan I, Bonavida B. Regulation of T Cells in Cancer by Nitric Oxide. Cells. 10. PMID 34685635 DOI: 10.3390/cells10102655 |
0.352 |
|
| 2021 |
Vivarelli S, Falzone L, Candido S, Bonavida B, Libra M. YY1 Silencing Induces 5-Fluorouracil-Resistance and Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. International Journal of Molecular Sciences. 22. PMID 34445183 DOI: 10.3390/ijms22168481 |
0.314 |
|
| 2021 |
Touboul R, Zaravinos A, Bonavida B. Defective Natural Killer Cells in Melanoma: Role of NKG2D in Pathogenesis and Immunotherapy. Critical Reviews in Immunology. 41: 45-76. PMID 34348002 DOI: 10.1615/CritRevImmunol.2021037186 |
0.349 |
|
| 2020 |
Wang Y, Hays E, Rama M, Bonavida B. Cell-mediated immune resistance in cancer. Cancer Drug Resistance (Alhambra, Calif.). 3: 232-251. PMID 35310881 DOI: 10.20517/cdr.2019.98 |
0.391 |
|
| 2020 |
Bonavida B. Cross-Talk Cell Signaling between Anti-CD20 Antibodies and Nitric Oxide Donors. Critical Reviews in Oncogenesis. 25: 291-300. PMID 33463947 DOI: 10.1615/Critrevoncog.2020036042 |
0.446 |
|
| 2020 |
Navasardyan I, Bonavida B. Reversal of Resistance to Anti-CD20 Antibody Therapies: Targeting Intracellular Resistant Factors. Critical Reviews in Oncogenesis. 25: 275-290. PMID 33463946 DOI: 10.1615/Critrevoncog.2020036109 |
0.454 |
|
| 2020 |
Vivarelli S, Falzone L, Ligresti G, Candido S, Garozzo A, Magro GG, Bonavida B, Libra M. Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. International Journal of Molecular Sciences. 21. PMID 32899428 DOI: 10.3390/Ijms21176446 |
0.489 |
|
| 2020 |
Bonavida B. Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs. Biochemical Pharmacology. 113913. PMID 32173364 DOI: 10.1016/J.Bcp.2020.113913 |
0.415 |
|
| 2019 |
Kosasih FR, Bonavida B. Involvement of Yin Yang 1 (YY1) Expression in T-Cell Subsets Differentiation and Their Functions: Implications in T Cell-Mediated Diseases. Critical Reviews in Immunology. 39: 491-510. PMID 32421959 DOI: 10.1615/Critrevimmunol.2020033272 |
0.371 |
|
| 2019 |
Navasardyan I, Bonavida B. Identifying Crosstalk between Raf Kinase Inhibitor Protein and Systemic Lupus Erythematosus. Critical Reviews in Immunology. 39: 423-437. PMID 32421956 DOI: 10.1615/Critrevimmunol.2020033377 |
0.354 |
|
| 2019 |
Hays E, Bonavida B. Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies. Antioxidants (Basel, Switzerland). 8. PMID 31533363 DOI: 10.3390/Antiox8090407 |
0.505 |
|
| 2019 |
Hays E, Bonavida B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 43: 10-28. PMID 31005030 DOI: 10.1016/J.Drup.2019.04.001 |
0.465 |
|
| 2018 |
Bonavida B. Linking Autophagy and the Dysregulated NFκB/ SNAIL/YY1/RKIP/PTEN Loop in Cancer: Therapeutic Implications. Critical Reviews in Oncogenesis. 23: 307-320. PMID 30311562 DOI: 10.1615/Critrevoncog.2018027212 |
0.427 |
|
| 2018 |
Wang Y, Bonavida B. A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics. Critical Reviews in Oncogenesis. 23: 281-305. PMID 30311561 DOI: 10.1615/Critrevoncog.2018027211 |
0.494 |
|
| 2018 |
Zaravinos A, Bonavida B, Chatzaki E, Baritaki S. RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact. Cancers. 10. PMID 30149591 DOI: 10.3390/Cancers10090287 |
0.493 |
|
| 2018 |
Bae S, Brumbaugh J, Bonavida B. Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironment. Genes & Cancer. 9: 87-100. PMID 30108680 DOI: 10.18632/Genesandcancer.172 |
0.418 |
|
| 2018 |
Bonavida B. Preface: Autophagy and Oncogenesis Critical Reviews™ in Oncogenesis. 23: v-vi. DOI: 10.1615/Critrevoncog.V23.I5-6.10 |
0.302 |
|
| 2017 |
Kaufhold S, Aziz N, Bonavida B. The Forgotten YY2 in Reported YY1 Expression Levels in Human Cancers. Critical Reviews in Oncogenesis. 22: 63-73. PMID 29604937 DOI: 10.1615/Critrevoncog.2017020475 |
0.388 |
|
| 2017 |
Cho AA, Bonavida B. Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis. Critical Reviews in Oncogenesis. 22: 49-61. PMID 29604936 DOI: 10.1615/Critrevoncog.2017020473 |
0.473 |
|
| 2017 |
Bonavida B. Therapeutic YY1 Inhibitors in Cancer: ALL in ONE. Critical Reviews in Oncogenesis. 22: 37-47. PMID 29604935 DOI: 10.1615/Critrevoncog.2017020472 |
0.459 |
|
| 2017 |
Hernandez-Cueto A, Hernandez-Cueto D, Antonio-Andres G, Mendoza-Marin M, Jimenez-Gutierrez C, Sandoval-Mejia AL, Mora-Campos R, Gonzalez-Bonilla C, Vega MI, Bonavida B, Huerta-Yepez S. [Corrigendum] Death receptor 5 expression is inversely correlated with prostate cancer progression. Molecular Medicine Reports. PMID 28849134 DOI: 10.3892/Mmr.2017.7234 |
0.323 |
|
| 2017 |
Shvartsur A, Givechian KB, Garban H, Bonavida B. Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma. Journal of Experimental & Clinical Cancer Research : Cr. 36: 62. PMID 28476134 DOI: 10.1186/S13046-017-0535-Z |
0.728 |
|
| 2017 |
Lee S, Wottrich S, Bonavida B. Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog). Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 39: 1010428317692253. PMID 28378634 DOI: 10.1177/1010428317692253 |
0.351 |
|
| 2017 |
Wottrich S, Kaufhold S, Chrysos E, Zoras O, Baritaki S, Bonavida B. Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 30: 28-38. PMID 28363333 DOI: 10.1016/J.Drup.2017.01.001 |
0.481 |
|
| 2017 |
Bonavida B, Chouaib S. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 457-467. PMID 27864216 DOI: 10.1093/annonc/mdw615 |
0.332 |
|
| 2016 |
Aziz N, Bonavida B. Activation of Natural Killer Cells by Probiotics. Forum On Immunopathological Diseases and Therapeutics. 7: 41-55. PMID 28616355 DOI: 10.1615/Forumimmundisther.2016017095 |
0.334 |
|
| 2016 |
Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene. 35: 5576. PMID 27345401 DOI: 10.1038/Onc.2016.207 |
0.562 |
|
| 2016 |
Kaufhold S, Garbán H, Bonavida B. Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. Journal of Experimental & Clinical Cancer Research : Cr. 35: 84. PMID 27225481 DOI: 10.1186/S13046-016-0359-2 |
0.696 |
|
| 2016 |
Bonavida B, Vega MI. PREFACE: Contrasting Roles of KLF4 as an Oncogene or Tumor Suppressor Forum On Immunopathological Diseases and Therapeutics. 7: 57-59. DOI: 10.1615/Forumimmundisther.2016018172 |
0.339 |
|
| 2016 |
Moyal E, Kaufhold S, Bonavida B. Identification of the Alternating Oncogenic and Tumor-Suppressor Activities of Kruppel-Like Factor 4 in Various Human Cancers Forum On Immunopathological Diseases and Therapeutics. 7: 77-93. DOI: 10.1615/Forumimmundisther.2016017233 |
0.364 |
|
| 2016 |
Wottrich S, Bonavida B. Regulation of the Cancer Stem Cell Phenotype by Raf Kinase Inhibitor Protein via Its Association with Kruppel-Like Factor 4 Forum On Immunopathological Diseases and Therapeutics. 7: 107-118. DOI: 10.1615/Forumimmundisther.2016017232 |
0.336 |
|
| 2016 |
Shvartsur A, Garban H, Bonavida B. Overexpression of Raf Kinase Inhibitor Protein (RKIP) in Multiple Myeloma and Its Molecular Signature Blood. 128: 5673-5673. DOI: 10.1182/Blood.V128.22.5673.5673 |
0.643 |
|
| 2016 |
Kaufhold S, Wottrich S, Garban H, Libra M, Bonavida B. Yin Yang 1 (YY1) Acting Primarily As an Oncogene and Rarely As a Tumor Suppressor in Distinct Hematological Malignancies: Prognostic and Therapeutic Implications Blood. 128: 5122-5122. DOI: 10.1182/Blood.V128.22.5122.5122 |
0.734 |
|
| 2016 |
Falzone L, Libra M, Bonavida B. Overexpression of the Transcription Factor Yin Yang 1 in Non-Hodgkin Lymphoma is associated with Chemo-Immune Resistance Clinical Lymphoma Myeloma and Leukemia. 16: S119-S120. DOI: 10.1016/J.Clml.2016.07.174 |
0.335 |
|
| 2015 |
Rapozzi V, Pietra ED, Bonavida B, Xodo LE. The Role Of Nitric Oxide After Repeated Low Dose Photodynamic Treatments In Prostate Carcinoma Cells. Redox Biology. 5: 422-423. PMID 28162294 DOI: 10.1016/J.Redox.2015.09.037 |
0.409 |
|
| 2015 |
Bonavida B. Regulation Of Cell Death Apoptotic Pathways By Nitric Oxide In Cancer: Reversal Of Drug/Immune Resistance. Redox Biology. 5: 415. PMID 28162274 DOI: 10.1016/J.Redox.2015.09.016 |
0.546 |
|
| 2015 |
Vega GG, Avilés-Salas A, Chalapud JR, Martinez-Paniagua M, Pelayo R, Mayani H, Hernandez-Pando R, Martinez-Maza O, Huerta-Yepez S, Bonavida B, Vega MI. P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma. Bmc Cancer. 15: 722. PMID 26475474 DOI: 10.1186/S12885-015-1778-8 |
0.368 |
|
| 2015 |
Muntané J, Bonavida B. Special collection: Nitric oxide in cancer. Redox Biology. 6: 505-6. PMID 26448395 DOI: 10.1016/J.Redox.2015.09.038 |
0.518 |
|
| 2015 |
Bonavida B, Garban H. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics. Redox Biology. 6: 486-94. PMID 26432660 DOI: 10.1016/J.Redox.2015.08.013 |
0.784 |
|
| 2015 |
Vega GG, Franco-Cea LA, Huerta-Yepez S, Mayani H, Morrison SL, Bonavida B, Vega MI. Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy. International Journal of Oncology. 47: 1735-48. PMID 26398317 DOI: 10.3892/Ijo.2015.3170 |
0.49 |
|
| 2015 |
Rapozzi V, Della Pietra E, Bonavida B. Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy. Redox Biology. 6: 311-7. PMID 26319434 DOI: 10.1016/J.Redox.2015.07.015 |
0.524 |
|
| 2015 |
Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes & Cancer. 6: 84-105. PMID 26000093 DOI: 10.18632/Genesandcancer.40 |
0.475 |
|
| 2015 |
Della Pietra E, Simonella F, Bonavida B, Xodo LE, Rapozzi V. Repeated sub-optimal photodynamic treatments with pheophorbide a induce an epithelial mesenchymal transition in prostate cancer cells via nitric oxide. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 45: 43-53. PMID 25700664 DOI: 10.1016/J.Niox.2015.02.005 |
0.408 |
|
| 2015 |
Bonavida B, Kaufhold S. Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: a therapeutic target. Pharmacology & Therapeutics. 150: 149-68. PMID 25619146 DOI: 10.1016/J.Pharmthera.2015.01.011 |
0.399 |
|
| 2015 |
Shvartsur A, Chatterjee D, Chen H, Berenson J, Garban H, Bonavida B. A Bioinformatics Approach Revealed a Differential Expression of RKIP-Related Genes in Pre-Multiple Myeloma and Multiple Myeloma: Clinical Implications Blood. 126: 5309-5309. DOI: 10.1182/Blood.V126.23.5309.5309 |
0.698 |
|
| 2015 |
Kaufhold S, Garban H, Bonavida B. In silico Tissue-Based Expression Analysis of YY1 and Cancer Stem Cell (CSC) Transcription Factors in Hematological Malignancies: Unraveling New Therapeutic Targets Blood. 126: 4814-4814. DOI: 10.1182/Blood.V126.23.4814.4814 |
0.712 |
|
| 2015 |
Vega GG, Franco-Cea LA, Huerta-Yepez S, Mayani H, Martinez-Maza O, Bonavida B, Vega MI. Cooperation Between the CD20 Receptor and hIFN-Alpha Receptor in Overriding the Blocked CD20 Cell-Signaling in Rituximab-Resistant B-NHL By the Fusion Protein Anti-CD20-hIFN-Alpha Blood. 126: 1468-1468. DOI: 10.1182/Blood.V126.23.1468.1468 |
0.401 |
|
| 2015 |
Montecillo-Aguado MR, Vega GG, Mayani H, Huerta-Yepez S, Bonavida B, Martinez-Maza O, Vega MI. KLF4 and YY1 Are Resistant Factors in NHL and Potential Therapeutic Targets: The New Resistant NF-κb/YY1/KLF4/BclxL/Mcl-1 Axis Blood. 126: 1466-1466. DOI: 10.1182/Blood.V126.23.1466.1466 |
0.566 |
|
| 2015 |
Montecillo-Aguado MR, Vega GG, Mayani H, Huerta-Yepez S, Hernández-Pando R, Martinez-Maza O, Bonavida B, Vega MI. Abstract 3617: Inhibition of KLF4 expression in resistant B-NHL cell lines inhibited cell growth and sensitized the cells to drug-induced apoptosis Cancer Research. 75: 3617-3617. DOI: 10.1158/1538-7445.Am2015-3617 |
0.564 |
|
| 2014 |
Bonavida B. RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loop. Critical Reviews in Oncogenesis. 19: 431-45. PMID 25597353 DOI: 10.1615/Critrevoncog.2014011929 |
0.495 |
|
| 2014 |
Bonavida B. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Seminars in Oncology. 41: 667-77. PMID 25440611 DOI: 10.1053/J.Seminoncol.2014.08.006 |
0.454 |
|
| 2014 |
Bonavida B, Fan J, Hiserodt JC. T-cell membrane antigens associated with cytotoxic function. Immunology Today. 3: 138-43. PMID 25291652 DOI: 10.1016/0167-5699(82)90074-3 |
0.332 |
|
| 2014 |
Hernandez-Cueto A, Hernandez-Cueto D, Antonio-Andres G, Mendoza-Marin M, Jimenez-Gutierrez C, Sandoval-Mejia AL, Mora-Campos R, Gonzalez-Bonilla C, Vega MI, Bonavida B, Huerta-Yepez S. Death receptor 5 expression is inversely correlated with prostate cancer progression. Molecular Medicine Reports. 10: 2279-86. PMID 25174820 DOI: 10.3892/Mmr.2014.2504 |
0.329 |
|
| 2014 |
Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. Journal of Experimental & Clinical Cancer Research : Cr. 33: 62. PMID 25084828 DOI: 10.1186/S13046-014-0062-0 |
0.454 |
|
| 2014 |
Kashyap V, Bonavida B. Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression. Genes & Cancer. 5: 71-83. PMID 25053986 DOI: 10.18632/Genesandcancer.12 |
0.383 |
|
| 2014 |
Huerta-Yepez S, Liu H, Baritaki S, Del Lourdes Cebrera-Muñoz M, Rivera-Pazos C, Maldonado-Valenzuela A, Valencia-Hipolito A, Vega MI, Chen H, Berenson JR, Bonavida B. Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance. International Journal of Oncology. 45: 1184-92. PMID 24970600 DOI: 10.3892/Ijo.2014.2511 |
0.466 |
|
| 2014 |
Bonavida B. NK cell phenotypic and functional heterogeneities and molecular mechanisms of cytotoxicity. Critical Reviews in Oncogenesis. 19: 21-45. PMID 24941371 DOI: 10.1615/Critrevoncog.2014010804 |
0.387 |
|
| 2014 |
Yousuf S, Duan M, Moen EL, Cross-Knorr S, Brilliant K, Bonavida B, LaValle T, Yeung KC, Al-Mulla F, Chin E, Chatterjee D. Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. Plos One. 9: e92478. PMID 24658061 DOI: 10.1371/Journal.Pone.0092478 |
0.441 |
|
| 2014 |
Valencia-Hipόlito A, Hernández-Atenógenes M, Vega GG, Maldonado-Valenzuela A, Ramon G, Mayani H, Peña Alonso Y, Martinez-Maza O, Méndez-Tenorio A, Huerta-Yepez S, Bonavida B, Vega MI. Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma. Leukemia & Lymphoma. 55: 1806-14. PMID 24067139 DOI: 10.3109/10428194.2013.848437 |
0.357 |
|
| 2014 |
Sanchez E, Gillespie A, Harutyunyan NM, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, Ghermezi M, Wang C, Ben-Zvi J, Garzio G, Finlay J, Bonavida B, Chen H, et al. Circulating Bcma Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients Blood. 124: 4713-4713. DOI: 10.1182/Blood.V124.21.4713.4713 |
0.322 |
|
| 2014 |
Chen H, Sanchez E, Li M, Wang C, Gillespie A, Shvartsur A, Vardanyan S, Harutyunyan NM, Garzio G, Tang G, Bonavida B, Berenson JR. Increased M2 Macrophages in Multiple Myeloma Patients with Progressive Disease and Down-Regulated Polarization with the JAK2 Inhibitor Ruxolitinib Blood. 124: 4106-4106. DOI: 10.1182/Blood.V124.21.4106.4106 |
0.389 |
|
| 2014 |
Chen H, Sanchez E, Li M, Wang C, Gillespie A, Shvartsur A, Vardanyan S, Harutyunyan NM, Garzio G, Tang G, Bonavida B, Berenson JR. Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids Blood. 124: 2114-2114. DOI: 10.1182/Blood.V124.21.2114.2114 |
0.443 |
|
| 2013 |
Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S. Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. Forum On Immunopathological Diseases and Therapeutics. 4. PMID 24187651 DOI: 10.1615/Forumimmundisther.2013008299 |
0.727 |
|
| 2013 |
Hariharan K, Chu P, Murphy T, Clanton D, Berquist L, Molina A, Ho SN, Vega MI, Bonavida B. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. International Journal of Oncology. 43: 670-6. PMID 23764770 DOI: 10.3892/Ijo.2013.1986 |
0.507 |
|
| 2013 |
Rapozzi V, Della Pietra E, Zorzet S, Zacchigna M, Bonavida B, Xodo LE. Nitric oxide-mediated activity in anti-cancer photodynamic therapy. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 30: 26-35. PMID 23357401 DOI: 10.1016/J.Niox.2013.01.002 |
0.468 |
|
| 2013 |
Huerta-Yepez S, Baritaki S, Baay-Guzman G, Hernandez-Luna MA, Hernandez-Cueto A, Vega MI, Bonavida B. Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 29: 17-24. PMID 23246440 DOI: 10.1016/J.Niox.2012.12.001 |
0.564 |
|
| 2013 |
Li M, Vardanyan S, Gottlieb J, Wang C, Delijani K, Halleluyan R, Ben-Zvi J, Song M, Sanchez E, Bonavida B, Chen H, Berenson JR. Higher TRAF6 and Fbxo 3 Expression Is With Progressive Multiple Myeloma and Blockage Of TRAF6 Inhibits Tumor Growth and Bone Resorption Blood. 122: 5362-5362. DOI: 10.1182/Blood.V122.21.5362.5362 |
0.466 |
|
| 2013 |
Chen H, Li M, Vardanyan S, Gottlieb J, Wang C, Delijani K, Ben-Zvi J, Song M, Halleluyan R, Sanchez E, Bonavida B, Berenson JR. Increased M2 Macrophages and Higher Levels Of The Tribble Family Member Trib1 In Monocytes Are Associated With Progressive Disease In Multiple Myeloma (MM) Patients Blood. 122: 3127-3127. DOI: 10.1182/Blood.V122.21.3127.3127 |
0.356 |
|
| 2013 |
Vega MI, Valencia-Hipolito A, Hernandez-Atenogenes M, Vega GG, Mayani H, Huerta-Yepez S, Bonavida B, Martinez-Maza O. Yin Yang 1 (YY1) Regulates The Transcription Of The Gene Krüppel-Like Factor 4 (KLF4) In Pediatric Burkitt Lymphoma: Clinical Implications Blood. 122: 3004-3004. DOI: 10.1182/Blood.V122.21.3004.3004 |
0.495 |
|
| 2013 |
Vega MI, Valencia-Hipolito A, Hernandez-Atenogenes M, Vega GG, Mayani H, Mendez-Tenorio A, Martinez-Maza O, Huerta-Yepez S, Bonavida B. Abstract 5450: High expression of Krüppel-Like Factor 4 (KLF4) and its regulation by Yin Yang 1 (YY1) in non-Hodgkin's B-cell lymphomas: clinical implication. Cancer Research. 73: 5450-5450. DOI: 10.1158/1538-7445.Am2013-5450 |
0.44 |
|
| 2013 |
Vega MI, Valencia-Hipolito A, Hernández-Atenógenes M, Vega GG, Mayani H, Huerta-Yepez S, Bonavida B. Abstract B199: Transcriptional regulation of KLF4 by Yin Yang 1 (YY1) in pediatric B-NHL and clinical significance. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B199 |
0.467 |
|
| 2013 |
Baritaki S, Rapozzi V, Pelayo R, Vega M, Huerta-Yepez S, Bonavida B. Abstract A53: Yin Yang 1 (YY1) regulates EMT via transcriptional activation of Snail and its overexpression in cancer stem cells (CSCs) in prostate cancer: Clinical significance. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A53 |
0.453 |
|
| 2012 |
Bonavida B, Baritaki S. Inhibition of Epithelial-to-Mesenchymal Transition (EMT) in Cancer by Nitric Oxide: Pivotal Roles of Nitrosylation of NF-κB, YY1 and Snail. Forum On Immunopathological Diseases and Therapeutics. 3: 125-133. PMID 24729932 DOI: 10.1615/Forumimmundisther.2012006065 |
0.509 |
|
| 2012 |
Baay-Guzman GJ, Bebenek IG, Zeidler M, Hernandez-Pando R, Vega MI, Garcia-Zepeda EA, Antonio-Andres G, Bonavida B, Riedi M, Kleerup E, Tashkin DP, Hankinson O, Huerta-Yepez S. HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: Implications in allergic airway inflammation Respiratory Research. 13. PMID 22823210 DOI: 10.1186/1465-9921-13-60 |
0.337 |
|
| 2012 |
Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. British Journal of Haematology. 158: 727-38. PMID 22804669 DOI: 10.1111/J.1365-2141.2012.09241.X |
0.31 |
|
| 2012 |
Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B. TRAF6 activation in multiple myeloma: a potential therapeutic target. Clinical Lymphoma, Myeloma & Leukemia. 12: 155-63. PMID 22440007 DOI: 10.1016/J.Clml.2012.01.006 |
0.445 |
|
| 2012 |
Martinez-Paniagua MA, Vega MI, Huerta-Yepez S, Baritaki S, Vega GG, Hariharan K, Bonavida B. Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs. Molecular Cancer Therapeutics. 11: 572-81. PMID 22267549 DOI: 10.1158/1535-7163.Mct-11-0635 |
0.598 |
|
| 2012 |
Bonavida B, Huerta-Yepez S, Baritaki S, Vega M, Liu H, Chen H, Berenson J. Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies. Critical Reviews in Oncogenesis. 16: 261-7. PMID 22248059 DOI: 10.1615/Critrevoncog.V16.I3-4.90 |
0.474 |
|
| 2012 |
Hourizadeh A, Broquet C, Menciahuerta J, Braquet P, Berek J, Bonavida B. Cytotoxicity of new aza-alkyl lysophospholipids against drug-sensitive and resistant human ovarian tumor-cell lines - role of free-radicals and potentiation of cytotoxicity by tnf-alpha and cddp. Oncology Reports. 1: 1253-9. PMID 21607526 DOI: 10.3892/Or.1.6.1253 |
0.485 |
|
| 2012 |
Morimoto H, Robin J, Broquet C, Menciahuerta J, Braquet P, Bonavida B. Cytotoxic activity against resistant human tumor-cell lines by 2 synthetic demethylpodophyllotoxin derivatives - a single stereoisomeric change prevents cell-death by apoptosis. International Journal of Oncology. 3: 1061-6. PMID 21573473 DOI: 10.3892/Ijo.3.6.1061 |
0.522 |
|
| 2012 |
Uslu R, Bonavida B. Free-radicals dependent and independent pathways of cddp-mediated cytotoxicity and apoptosis in ovarian tumor-cell lines. International Journal of Oncology. 6: 1003-9. PMID 21556631 DOI: 10.3892/Ijo.6.5.1003 |
0.485 |
|
| 2012 |
Demidem A, Salahuddin Z, Lam T, Levine A, Khan R, Hober D, Bonavida B. Sensitization of AIDS related non-Hodgkin's B lymphoma cell lines to cytotoxic drugs toxins by interferon-gamma. International Journal of Oncology. 8: 461-8. PMID 21544383 DOI: 10.3892/Ijo.8.3.461 |
0.484 |
|
| 2012 |
Bonavida B, Baritaki S. Stable Water Clusters-Mediated Molecular Alterations in Human Melanoma Cell Lines Forum On Immunopathological Diseases and Therapeutics. 3: 253-259. DOI: 10.1615/Forumimmundisther.2013007833 |
0.302 |
|
| 2012 |
Sanchez E, Li M, Kitto A, Li J, Wang C, Kirk DT, Robinson A, Madden E, Okhovat J, Waterman GN, Swift RA, Bonavida B, Chen H, Berenson JR. Evaluation of serum B-cell maturation antigen in multiple myeloma. Journal of Clinical Oncology. 30: e18549-e18549. DOI: 10.1200/Jco.2012.30.15_Suppl.E18549 |
0.339 |
|
| 2012 |
Chen H, Li M, Li J, Delijani K, Rauch D, DeCorso K, Prajogi A, Wang CS, Sanchez E, Bonavida B, Berenson JR. Anti-Myeloma Effects of the Janus Kinase 2 (JAK2) Inhibitor SAR503 Alone and in Combination Treatment Blood. 120: 4986-4986. DOI: 10.1182/Blood.V120.21.4986.4986 |
0.498 |
|
| 2012 |
Vega MI, Hariharan H, Chu P, Murphy T, Clanton D, Berquist L, Molina A, Ho S, Bonavida B. Inhibition of B-NHL Tumor Xenografts Following Treatment with Galiximab (Anti-CD80 mAb) and Potentiation When Combined with Chemotherapy Blood. 120: 4873-4873. DOI: 10.1182/Blood.V120.21.4873.4873 |
0.494 |
|
| 2012 |
Chen H, Li J, Delijani K, Rauch D, DeCorso K, Prajogi A, Wang CS, Sanchez E, Bonavida B, Berenson JR. Decreased LIMD1 Gene Expression Is Associated with HIF-1α Over-Expression and Angiogenesis in Multiple Myeloma Blood. 120: 1829-1829. DOI: 10.1182/Blood.V120.21.1829.1829 |
0.375 |
|
| 2012 |
Vega GG, Martinez-Paniagua MA, Huerta-Yepez S, Baritaki S, Hariharan K, Mayani H, Vega MI, Bonavida B. Abstract 766: Galiximab disrupts the dysregulated NF-κB/YY1/Snail/BclXLcircuit that regulates the resistance of B-NHL cell lines: Sensitization to chemo-immunotherapeutic drugs Cancer Research. 72: 766-766. DOI: 10.1158/1538-7445.Am2012-766 |
0.535 |
|
| 2012 |
Valencia-Hipólito A, Hernandez-Atenogenes M, Vega GG, Martinez-Paniagua MA, Aguilar-Martinez M, Hernadez-Pando R, Ramon-Garcia G, Mayani H, Martinez-Maza O, Huerta-Yepez S, Bonavida B, Vega MI. Abstract 4582: Regulation of Krüppel-Like Factor 4 (KLF4) expressions via Yin Yang 1 (YY1) in B Non-Hodgkin's Lymphomas (B-NHLs): KLF4 upregulation is associated with unfavorable overall survival in pediatric B-NHL Cancer Research. 72: 4582-4582. DOI: 10.1158/1538-7445.Am2012-4582 |
0.437 |
|
| 2012 |
Andres-Antonio G, Rangel-Santiago J, Tirado-Rodriguez AB, Dorantes-Acosta E, Vega MI, Aquino-Jarquin G, Lopez B, Jimenez E, Pelayo R, Bonavida B, Medina-Sanson A, Huerta-Yepez S. Abstract 4330: Transcriptional regulation of gp170 by YY1 and prognostic significance in childhood acute lymphoblastic leukemia (ALL) Cancer Research. 72: 4330-4330. DOI: 10.1158/1538-7445.Am2012-4330 |
0.429 |
|
| 2011 |
Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B. Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. Forum On Immunopathological Diseases and Therapeutics. 2. PMID 24286018 DOI: 10.1615/Forumimmundisther.V2.I2.90 |
0.458 |
|
| 2011 |
Bonavida B, Baritaki S. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry. Critical Reviews in Oncogenesis. 16: 211-26. PMID 22248055 DOI: 10.1615/Critrevoncog.V16.I3-4.50 |
0.476 |
|
| 2011 |
RodrÃguez JA, Luria-Pérez R, López-Valdés HE, Casero D, Daniels TR, Patel S, Avila D, Leuchter R, So S, Ortiz-Sánchez E, Bonavida B, MartÃnez-Maza O, Charles AC, Pellegrini M, Helguera G, et al. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leukemia & Lymphoma. 52: 2169-78. PMID 21870996 DOI: 10.3109/10428194.2011.596964 |
0.363 |
|
| 2011 |
Martínez-Paniagua MA, Baritaki S, Huerta-Yepez S, Ortiz-Navarrete VF, González-Bonilla C, Bonavida B, Vega MI. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle (Georgetown, Tex.). 10: 2792-805. PMID 21822052 DOI: 10.4161/Cc.10.16.16952 |
0.537 |
|
| 2011 |
Huerta-Yepez S, Yoon NK, Hernandez-Cueto A, Mah V, Rivera-Pazos CM, Chatterjee D, Vega MI, Maresh EL, Horvath S, Chia D, Bonavida B, Goodglick L. Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. Bmc Cancer. 11: 259. PMID 21689459 DOI: 10.1186/1471-2407-11-259 |
0.319 |
|
| 2011 |
Daniels TR, Ortiz-Sánchez E, Luria-Pérez R, Quintero R, Helguera G, Bonavida B, MartÃnez-Maza O, Penichet ML. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 500-8. PMID 21654517 DOI: 10.1097/Cji.0B013E318222Ffc8 |
0.376 |
|
| 2011 |
Jazirehi AR, Bonavida B. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 731: 407-19. PMID 21516425 DOI: 10.1007/978-1-61779-080-5_33 |
0.729 |
|
| 2011 |
Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. International Journal of Oncology. 38: 1683-94. PMID 21455568 DOI: 10.3892/Ijo.2011.984 |
0.506 |
|
| 2011 |
Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Current Cancer Drug Targets. 11: 254-84. PMID 21247382 DOI: 10.2174/156800911794519716 |
0.44 |
|
| 2011 |
Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Research. 71: 1406-17. PMID 21159666 DOI: 10.1158/0008-5472.Can-10-1296 |
0.731 |
|
| 2011 |
Vega MI, Baritaki S, Huerta-Yepez S, Martinez-Paniagua MA, Bonavida B. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Leukemia & Lymphoma. 52: 108-21. PMID 21133714 DOI: 10.3109/10428194.2010.531408 |
0.577 |
|
| 2011 |
Bonavida B, Baritaki S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 24: 1-7. PMID 20933602 DOI: 10.1016/J.Niox.2010.10.001 |
0.561 |
|
| 2011 |
Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leukemia Research. 35: 373-9. PMID 20650529 DOI: 10.1016/J.Leukres.2010.06.026 |
0.46 |
|
| 2011 |
Bonavida B. Induction of RKIP Expression by Anticancer Therapeutic Antibodies and Its Role in the Reversal of Chemo- and Immunoresistance Forum On Immunopathological Diseases and Therapeutics. 2: 119-126. DOI: 10.1615/Forumimmundisther.V2.I2.30 |
0.346 |
|
| 2011 |
Baritaki S, Yeung KC, Bonavida B. Dual Roles of Raf-1 Kinase Inhibitor Protein in the Regulation of Both Tumor Cell Resistance to Apoptotic Stimuli and Epithelial to Mesenchymal Transition Forum On Immunopathological Diseases and Therapeutics. 2: 95-109. DOI: 10.1615/Forumimmundisther.V2.I1.110 |
0.429 |
|
| 2011 |
Bonavida B, Atassi MZ. COMMENTARY: Molecular and Biochemical Mechanisms of Photodynamic Therapy Anti-Tumor Effects Forum On Immunopathological Diseases and Therapeutics. 2: 277-280. DOI: 10.1615/Forumimmundisther.2012004607 |
0.339 |
|
| 2011 |
Rapozzi V, Bonavida B, Xodo LE. Pivotal Role of Nitric Oxide (NO) Induction by Photodynamic Therapy in Tumor Cells: Modification of the NF-κB/Snail/RKIP Survival/Anti-Apoptotic Loop Forum On Immunopathological Diseases and Therapeutics. 2: 205-214. DOI: 10.1615/Forumimmundisther.2011004418 |
0.416 |
|
| 2011 |
Vega MI, Hernandez-Atenogenes M, Valencia A, Vega GG, Maldonado-Valenzuela A, Ramon G, Chen H, Berenson JR, Martinez-Maza O, Mayani H, Huerta-Yepez S, Bonavida B. Upregulation of KLF4 Expression in Pediatric B-NHL Lymphomas and Its Association with Low EFS and Poor Survival Following Treatment with Chemotherapy Blood. 118: 5184-5184. DOI: 10.1182/Blood.V118.21.5184.5184 |
0.467 |
|
| 2011 |
Chen H, Li M, Li J, Dreyer MP, Ahles CP, Lee T, Qiu JT, Wang C, Sanchez E, Bonavida B, Levy O, Dassa L, Cojocaru G, Levine Z, Berenson JR. Blockage of CGEN-928 Expression Down-Regulates AKT Signaling Pathway and Inhibits Multiple Myeloma (MM) Cell Proliferation Blood. 118: 5102-5102. DOI: 10.1182/Blood.V118.21.5102.5102 |
0.502 |
|
| 2011 |
Liu H, Huerta-Yepez S, Rivera-Pazos CM, Cabera-Muñoz MdL, Baritaki S, Vardanyan S, Penichet ML, Chen H, Berenson JR, Bonavida B. Targeting the Over-Expressed Transcription Factor Yin-Yang 1 (YY1) Sensitizes Resistant Multiple Myeloma (MM) Cell Lines to Apoptosis by Bortezomib or Melphalan, Blood. 118: 3991-3991. DOI: 10.1182/Blood.V118.21.3991.3991 |
0.552 |
|
| 2011 |
andres-Antonio G, Rangel-Santiago J, Tirado-Rodriguez AB, Dorantes-Acosta E, Vega MI, Aquino-Jarquin G, Lopez B, Jimenez E, Pelayo R, Bonavida B, Medina-Sanson A, Huerta-Yepez S. Co-Overexpression of YY1 and Gp-170 (MDR1) in Childhood Acute Lymphocytic Leukemia (ALL): Transcription Regulation of Gp-170 by YY1 and Prognostic Significance, Blood. 118: 3567-3567. DOI: 10.1182/Blood.V118.21.3567.3567 |
0.409 |
|
| 2011 |
Vega GG, Vega MI, Huerta-Yepez S, Jazirehi A, Mayani H, Martinez-Maza O, Morrison S, Bonavida B. Cytotoxic Activity of Anti-CD20-hIFN-α on Rituximab-Resistant B-NHL Clones and Synergy with Chemotherapy, Blood. 118: 3499-3499. DOI: 10.1182/Blood.V118.21.3499.3499 |
0.706 |
|
| 2011 |
Li M, Dreyer MP, Ahles CP, Ramirez D, Nichols CM, Lee T, Song M, Wang CS, Sanchez E, Chen H, Bonavida B, Berenson JR. TRAF6 Dominant Negative Peptides Block Intracellular Signaling Resulting in Anti-Myeloma and Anti-Bone Resorptive Effects in Multiple Myeloma Blood. 118: 2919-2919. DOI: 10.1182/Blood.V118.21.2919.2919 |
0.465 |
|
| 2011 |
Li J, Leu A, Li M, Hobel ED, Delijani K, Qiu JT, Ramirez D, Lam AC, Wang C, Sanchez E, Bonavida B, Chen H, Berenson JR. Frequent Dysregulation of Fc Gamma Receptor IIb (Fc γRIIb) and Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Signaling Occurs in Multiple Myeloma (MM) Patients Blood. 118: 2917-2917. DOI: 10.1182/Blood.V118.21.2917.2917 |
0.42 |
|
| 2011 |
Huerta-Yepez S, Baritaki S, Liu H, Mendez-Maldonado KM, Penichet ML, Vega MI, Martinez-Maza O, Chen H, Berenson JR, Chatterjee D, Bonavida B. The Overexpression of Inactive Phosphorylated Raf-1 Kinase Inhibitory Protein (RKIP) in Multiple Myeloma (MM) Regulates the Resistance to Bortezomib-Induced Cytotoxicity: Reversal of Resistance by the PKC Inhibitor Bisindolylmalemide Blood. 118: 2892-2892. DOI: 10.1182/Blood.V118.21.2892.2892 |
0.532 |
|
| 2011 |
Vega MI, Aviles-Salas A, Chalapud JR, Huerta-Yepez S, Hernandez-Pando R, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Atenogenes M, Vega GG, Chen H, Berenson JR, Mayani H, Martinez-Maza O, Bonavida B. Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL Blood. 118: 2647-2647. DOI: 10.1182/Blood.V118.21.2647.2647 |
0.413 |
|
| 2011 |
Chen H, Sanchez E, Wang CS, Li M, Li J, Delijani KD, Li Z, Bonavida B, Levitt D, Berenson JR. Abstract LB-305: The tyrosine kinase inhibitor bafetinib (INNO-406) inhibits osteoclast formation and bone resorption Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-305 |
0.317 |
|
| 2011 |
Daniels TR, Ortiz-Sanchez E, Luria-Perez R, Quintero R, Helguera G, Bonavida B, Martinez-Maza O, Penichet ML. Abstract 3622: An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of multiple myeloma Cancer Research. 71: 3622-3622. DOI: 10.1158/1538-7445.Am2011-3622 |
0.38 |
|
| 2011 |
Martinez-Paniagua MA, Huerta-Yepez S, Baritaki S, Gonzalez-Bonilla CR, Bonavida B, Vega MI. Abstract 3499: Identification of a novel mechanism by which the BH3 mimetic obatoclax sensitizes non-Hodgkin's lymphoma tumor cells to TRAIL-mediated apoptosis Cancer Research. 71: 3499-3499. DOI: 10.1158/1538-7445.Am2011-3499 |
0.603 |
|
| 2011 |
Baritaki S, Yeung K, Huerta-Yepez S, Bonavida B. Abstract 2162: Inhibition of the metastasis suppressor RKIP by EZH2 and YY1 Cellular and Molecular Biology. 71: 2162-2162. DOI: 10.1158/1538-7445.Am2011-2162 |
0.318 |
|
| 2010 |
Baritaki S, Huerta-Yepez S, Sahakyan A, Karagiannides I, Bakirtzi K, Jazirehi A, Bonavida B. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle (Georgetown, Tex.). 9: 4931-40. PMID 21150329 DOI: 10.4161/Cc.9.24.14229 |
0.722 |
|
| 2010 |
Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes & Cancer. 1: 409-420. PMID 20827424 DOI: 10.1177/1947601910373795 |
0.397 |
|
| 2010 |
Mizutani Y, Katsuoka Y, Bonavida B. Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. International Journal of Oncology. 37: 503-8. PMID 20596678 DOI: 10.3892/Ijo_00000699 |
0.343 |
|
| 2010 |
Chen H, Wang CS, Li M, Sanchez E, Li J, Berenson A, Wirtschafter E, Wang J, Shen J, Li Z, Bonavida B, Berenson JR. A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay. International Journal of Oncology. 37: 71-9. PMID 20514398 DOI: 10.3892/Ijo_00000654 |
0.348 |
|
| 2010 |
Suzuki E, Daniels TR, Helguera G, Penichet ML, Umezawa K, Bonavida B. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. International Journal of Oncology. 36: 1299-307. PMID 20372806 DOI: 10.3892/Ijo_00000615 |
0.488 |
|
| 2010 |
Baritaki S, Bonavida B. Viral infection and cancer: the NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes. Critical Reviews in Immunology. 30: 31-46. PMID 20370618 DOI: 10.1615/Critrevimmunol.V30.I1.20 |
0.55 |
|
| 2010 |
Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B, Li ZW, Chen H, Berenson JR. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. British Journal of Haematology. 148: 569-81. PMID 19958357 DOI: 10.1111/J.1365-2141.2009.08008.X |
0.413 |
|
| 2010 |
Militello L, Baritaki S, Suzuki E, Vega MI, Salcedo M, Bonavida B. The anti-CD20 Mab R603 induces PTEN and RKIP expression in B-NHL cells: role in inhibition of constitutively activated Akt and NF-κB survival anti-apoptotic pathways F1000research. 1. DOI: 10.7490/F1000Research.91.1 |
0.457 |
|
| 2010 |
Huerta S, Gao X, Bonavida B. DETANONOate Is a Potent Chemo\ Radio-Sensitizing Agent in Colon and Colorectal Cancers as Assessed in In Vitro and In Vivo Established Tumor Xenografts Forum On Immunopathological Diseases and Therapeutics. 1: 281-295. DOI: 10.1615/Forumimmundisther.V1.I4.30 |
0.354 |
|
| 2010 |
Baritaki S, Bonavida B. Inhibition of Snail-induced Epithelial-Mesenchymal Transition and Induction of the Tumor Metastasis Suppressor Gene Raf-1 Kinase Inhibitor Protein (RKIP) by DETANONOate Forum On Immunopathological Diseases and Therapeutics. 1: 219-230. DOI: 10.1615/Forumimmundisther.V1.I3.40 |
0.374 |
|
| 2010 |
Libra M, Torrisi E, Castellano G, Nicoletti F, Malaponte G, Mazzarino MC, Marconi A, Proietti L, Militello L, Bonavida B, Stivala F, Canevari S. Computational evaluation of yin yang 1 transcript levels in the spectrum of B-cell neoplasia Forum On Immunopathological Diseases and Therapeutics. 1: 115-125. DOI: 10.1615/Forumimmundisther.V1.I1-2.80 |
0.43 |
|
| 2010 |
Bonavida B, Huerta-Yepez S, Jazirehi AR, Militello L, Uematsu N, Spandidos DA, Baritaki S, Vega MI. Clinical Significance of the Inhibition of YY1 Activity and Expression by Therapeutic Anti-Cancer Antibodies Forum On Immunopathological Diseases and Therapeutics. 1: 81-95. DOI: 10.1615/Forumimmundisther.V1.I1-2.60 |
0.721 |
|
| 2010 |
Rapozzi V, Huerta-Yepez S, Joshi A, Vega MI, Baritaki S, Xodo LE, Bonavida B. Photodynamic Therapy (PDT)-Mediated Inhibition of the Transcription Factor Yin Yang 1 (YY1) That Regulates Resistance In Lymphoma Blood. 116: 5113-5113. DOI: 10.1182/Blood.V116.21.5113.5113 |
0.545 |
|
| 2010 |
Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Baritaki S, Chen H, Berenson JR, Bonavida B. Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab Blood. 116: 4931-4931. DOI: 10.1182/Blood.V116.21.4931.4931 |
0.506 |
|
| 2010 |
Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Baritaki S, Bonavida B. An ADCC-Independent Mechanism of Rituximab-Mediated B-NHL Cells Depletion Via Sensitization to Cell Death through the Expression of TRAIL on NK Cells Blood. 116: 4919-4919. DOI: 10.1182/Blood.V116.21.4919.4919 |
0.551 |
|
| 2010 |
Li J, Li M, Wang C, Wang J, Sanchez E, Li Z, Bonavida B, Chen H, Berenson JR. Lack of Binding of Monoclonal Protein Produced by Multiple Myeloma (MM) Cells to FcγRIIb Reduces Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Signaling and Provides the Rationale for a Novel Therapeutic Approach to MM Blood. 116: 455-455. DOI: 10.1182/Blood.V116.21.455.455 |
0.466 |
|
| 2010 |
Li M, Sanchez E, Wang C, Schultz M, Wang J, Wong E, Li Z, Chen H, Bonavida B, Chou EE, Berenson JR. Blockage of TRAF6 by Dominant Negative Peptides to Inhibit Multiple Myeloma (MM) Cell Proliferation and Osteoclast Formation through NF-κB, JNK and AKT Signal Transduction Pathways Blood. 116: 4068-4068. DOI: 10.1182/Blood.V116.21.4068.4068 |
0.455 |
|
| 2010 |
Chen H, Li M, Wang C, Wang J, Sanchez E, Li Z, Bonavida B, Levy O, Dassa L, Cojocaru G, Berenson JR, Levine Z. Multiple Myeloma (MM) Highly Expresses CGEN-928 and the Anti-CGEN-928 TM21 Antibody Markedly Inhibits the Growth of MM Cells and Enhances the Anti-Myeloma Effects of Dexamethasone, Melphalan and Bortezomib Blood. 116: 4067-4067. DOI: 10.1182/Blood.V116.21.4067.4067 |
0.496 |
|
| 2010 |
Baritaki S, Suzuki E, Vega MI, Chen H, Berenson JR, Bonavida B. Rituximab Inhibits the PI3K/Akt Survival Pathway In B-NHL Cells Via Induction of the PTEN Tumor Suppressor: Pivotal Roles of the Inhibition of the PTEN Repressors Snail and YY1 Blood. 116: 3152-3152. DOI: 10.1182/Blood.V116.21.3152.3152 |
0.561 |
|
| 2010 |
Martinez-Paniagua M, Vega MI, Huerta-Yepez S, Hariharan H, Chen H, Berenson JR, Bonavida B. The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bclxl) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy Blood. 116: 2887-2887. DOI: 10.1182/Blood.V116.21.2887.2887 |
0.591 |
|
| 2010 |
Vega MI, Hernandez-Atenógenes M, Vazquez-Islas JC, Martinez-Miguel B, Martinez-Paniagua MA, Antonio-Andres G, Rivera-Pazos CM, Maldonado-Valenzuela A, Martinez-Maza O, Huerta-Yepez S, Bonavida B. Abstract 806: Upregulation of Krüppel-like Factor 4 (KLF-4) expression as a potential tumor progression gene product in non-Hodgkin's lymphoma Cancer Research. 70: 806-806. DOI: 10.1158/1538-7445.Am10-806 |
0.406 |
|
| 2010 |
Martinez-Paniagua MA, Vega MI, Huerta-Yepez S, Hariharan H, Bonavida B. Abstract 664: Galiximab (anti-CD80 mAb) sensitizes TRAIL-resistant B-lymphoma to TRAIL-induced apoptosis via inhibition of the transcription repressor Yin Yang 1 (YY1) Cancer Research. 70: 664-664. DOI: 10.1158/1538-7445.Am10-664 |
0.583 |
|
| 2010 |
Huerta-Yepez S, Suhendan E, Rivera-Pazos CM, Antonio-Andres G, Vega MI, Baay-Guzman G, Malaponte G, Baritaki S, Yeung K, Grimm E, Bonavida B. Abstract 3374: BRAF and NRAS mutations in melanoma regulate the phosphorylation and inactivation of RKIP, the metastasis suppressor and immune surveillance cancer gene product Cancer Research. 70: 3374-3374. DOI: 10.1158/1538-7445.Am10-3374 |
0.442 |
|
| 2010 |
Martinez-Miguel B, Paniagua MM, Huerta-Yepez S, Gonzalez-Bonilla C, Vega-Paredes M, Martinez-Maza O, Bonavida B. Abstract 2422: The trimeric engineered fusion protein with CD154 peptide mimetic (OmpC-CD154p), induced apoptotic signaling in B-NHL cell lines mediated by caspase 3 and caspase 8 activation Cancer Research. 70: 2422-2422. DOI: 10.1158/1538-7445.Am10-2422 |
0.46 |
|
| 2010 |
Baritaki S, Huerta-Yepez S, Yeung K, Neonakis I, Bonavida B. Abstract 2290: A novel function in metastasis for YY1 overexpression in the initiation of the EMT phenotype Cancer Research. 70: 2290-2290. DOI: 10.1158/1538-7445.Am10-2290 |
0.498 |
|
| 2010 |
Huerta-Yepez S, Suhendan E, Antonio-Andres G, Rivera-Pazos CM, Baay-Guzman G, Vega MI, Malaponte G, Jazirehi A, Baritaki S, Grimm E, Bonavida B. Abstract 2242: Correlation between the overexpression of the metastasis-inducer transcription factors Snail and Yin Yang 1 andBRAFmutations in a large panel of melanoma cell lines Cancer Research. 70: 2242-2242. DOI: 10.1158/1538-7445.Am10-2242 |
0.433 |
|
| 2010 |
Jazirehi AR, Baritaki S, Bonavida B, Economou JS. Abstract 1928: Resistance of human melanoma to MART-1/HLA A2.1 specific CTL (F5 CTL)-killing: poor recognition, low MART-1 expression and reversal of resistance Cancer Research. 70: 1928-1928. DOI: 10.1158/1538-7445.Am10-1928 |
0.454 |
|
| 2010 |
Baritaki S, Huerta-Yepez S, Sahakyan A, Jazirehi AR, Yeung K, Bonavida B. Abstract 1466: The NO donor DETANONOate inhibits the EMT phenotype in human metastatic prostate carcinoma cell lines: pivotal roles of inhibition of NF-κB and Snail activities and induction of RKIP Cancer Research. 70: 1466-1466. DOI: 10.1158/1538-7445.Am10-1466 |
0.5 |
|
| 2009 |
Vega MI, Martínez-Paniagua M, Huerta-Yepez S, González-Bonilla C, Uematsu N, Bonavida B. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization. International Journal of Oncology. 35: 1289-96. PMID 19885551 DOI: 10.3892/Ijo_00000446 |
0.494 |
|
| 2009 |
Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6582-94. PMID 19861448 DOI: 10.1158/1078-0432.Ccr-09-1234 |
0.715 |
|
| 2009 |
Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Research. 69: 8376-85. PMID 19843864 DOI: 10.1158/0008-5472.Can-09-1069 |
0.548 |
|
| 2009 |
Yoon NK, Seligson DB, Chia D, Elshimali Y, Sulur G, Li A, Horvath S, Maresh E, Mah V, Bose S, Bonavida B, Goodglick L. Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. Cancer Biomarkers : Section a of Disease Markers. 5: 215-24. PMID 19729831 DOI: 10.3233/Cbm-2009-0106 |
0.306 |
|
| 2009 |
Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene. 28: 3573-85. PMID 19633685 DOI: 10.1038/Onc.2009.214 |
0.483 |
|
| 2009 |
Wu K, Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Critical Reviews in Immunology. 29: 241-54. PMID 19538137 DOI: 10.1615/Critrevimmunol.V29.I3.40 |
0.55 |
|
| 2009 |
Sieber S, Gdynia G, Roth W, Bonavida B, Efferth T. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. International Journal of Oncology. 35: 149-58. PMID 19513562 DOI: 10.3892/Ijo_00000323 |
0.528 |
|
| 2009 |
Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA. BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle (Georgetown, Tex.). 8: 1402-8. PMID 19342899 DOI: 10.4161/Cc.8.9.8308 |
0.311 |
|
| 2009 |
Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Current Pharmaceutical Design. 15: 792-808. PMID 19275643 DOI: 10.2174/138161209787582156 |
0.562 |
|
| 2009 |
Huerta S, Baay-Guzman G, Gonzalez-Bonilla CR, Livingston EH, Huerta-Yepez S, Bonavida B. In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 20: 182-94. PMID 19105980 DOI: 10.1016/J.Niox.2008.11.006 |
0.572 |
|
| 2009 |
Chen H, Campbell RA, Chang Y, Li M, Wang CS, Li J, Sanchez E, Share M, Steinberg J, Berenson A, Shalitin D, Zeng Z, Gui D, Perez-Pinera P, Berenson RJ, ... ... Bonavida B, et al. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood. 113: 1992-2002. PMID 19060246 DOI: 10.1182/Blood-2008-02-133751 |
0.419 |
|
| 2009 |
Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, Bonavida B. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1 Nitric Oxide - Biology and Chemistry. 20: 39-52. PMID 18778787 DOI: 10.1016/J.Niox.2008.08.001 |
0.55 |
|
| 2009 |
Li M, Sanchez E, Li J, Wang CS, Shen J, Hu M, Leung C, Wang J, Wong E, Adler A, Li Z, Chen H, Bonavida B, Berenson JR. TRAF6-Dominant Negative Peptides Show Potent Inhibitory Effects On Multiple Myeloma, Osteoclast Formation and Bone Resorption. Blood. 114: 611-611. DOI: 10.1182/Blood.V114.22.611.611 |
0.391 |
|
| 2009 |
Vega MI, vazquez-Islas J, Martinez-Paniagua M, Hernandez-Atenogenes M, martinez-Miguel B, Maldonado-Valenzuela A, Gonzalez-Bonilla C, Huerta-Yepez S, Martinez-Maza O, Bonavida B. Upregulation of Krüppel-Like Factor 4 (KLF-4) Expression as a Potential Tumor Progression Gene Product in Non-Hodgkin's Lymphoma. Blood. 114: 5022-5022. DOI: 10.1182/Blood.V114.22.5022.5022 |
0.391 |
|
| 2009 |
Li Z, Leung C, Hu M, Xiang J, Jiang C, Steinberg JA, Shen J, Li M, Wang CS, Sanchez E, Bonavida B, Chen H, Bai X, Berenson JR. CC102528: A Novel Histone Deacetylase Inhibitor in the Hydroxamate Family Demonstrates Potent Anti-Myeloma Activity. Blood. 114: 4927-4927. DOI: 10.1182/Blood.V114.22.4927.4927 |
0.423 |
|
| 2009 |
Li Z, Hu M, Leung C, Steinberg JA, Shen J, Li M, Wang CS, Sanchez E, Bowers A, Greshock T, Miller K, Newkirk T, West N, Bradner JE, Williams RM, ... Bonavida B, et al. Largazole, a Novel Cyclic Peptide Histone Deacetylase Inhibitor, Demonstrates Anti-MM Effects Alone and Increases the Anti-MM Effects of Bortezomib. Blood. 114: 4925-4925. DOI: 10.1182/Blood.V114.22.4925.4925 |
0.437 |
|
| 2009 |
Antonio-Andres G, Pelayo R, Dorantes-Acosta E, Lopez-Martinez B, Tirado-Rodriguez B, Diaz-Elizondo G, Vega MI, Arriaga-Pizano L, Baay-Guzmán GJ, Hernandez-Cueto D, Bonavida B, Medina-Sanson A, Huerta-Yepez S. High Expression of Transcription Factor Yin Yang 1 and Multidrug Resistance Protein in Early B-Cell Precursors in Childhood Acute Lymphoblastic Leukemia. Blood. 114: 4695-4695. DOI: 10.1182/Blood.V114.22.4695.4695 |
0.515 |
|
| 2009 |
Baritaki S, Yeung K, Wu K, Chen H, Berenson JR, Palladino MA, Bonavida B. Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis. Blood. 114: 3938-3938. DOI: 10.1182/Blood.V114.22.3938.3938 |
0.553 |
|
| 2009 |
Chen H, Hao R, Sanchez E, Shen J, Li M, Wang J, Wong E, Adler A, Hu M, Leung C, Wang CS, Li Z, Bonavida B, Berenson JR. Pterostilbene: A Novel Histone Deacetylase 1 Inhibitor (HDACi1) Demonstrating Efficacy in Multiple Myeloma. Blood. 114: 3844-3844. DOI: 10.1182/Blood.V114.22.3844.3844 |
0.516 |
|
| 2009 |
Wirtschafter E, Wong E, Li M, Sanchez E, Wang CS, Li J, Kessler R, Hu M, Leung C, Li Z, Chen H, Bonavida B, Berenson JR. Pleiotrophin Is Highly Produced by Solid Tumors and Transdifferentiates Human Monocytes Into Endothelial Cells. Blood. 114: 3050-3050. DOI: 10.1182/Blood.V114.22.3050.3050 |
0.441 |
|
| 2009 |
Militello L, Baritaki S, Suzuki E, Vega MI, Salcedo M, Bonavida B. The Anti-CD 20 Mab R603 Induces PTEN and RKIP Expression in B-NHL Cells: Role in Inhibition of Constitutively Activated Akt and NF-ΚB Survival Anti-Apoptotic Pathways. Blood. 114: 1970-1970. DOI: 10.1182/Blood.V114.22.1970.1970 |
0.54 |
|
| 2009 |
Huerta-Yepez S, Vega MI, Rivera-Pazos C, Martinez-Maza O, Berenson JR, Bonavida B. Inverse Relationship Between the Transcription Repressor Yin Yang 1 (YY1) and the TRAIL Death Receptor DR5 in AIDS-Related Non-Hodgkin's Lymphoma Tissues: Potential Prognostic Biomarkers and Targets for Therapeutic Intervention. Blood. 114: 1932-1932. DOI: 10.1182/Blood.V114.22.1932.1932 |
0.493 |
|
| 2009 |
Li Z, Shalitin D, Finefield J, Leung C, Hu M, Shen J, Li M, Wang CS, Steinberg JA, Sanchez E, Chen H, Williams RM, Bonavida B, Berenson JR. Multiple Myeloma-Specific Targeted Therapy: Use of the Tumor Specific Immunoglobulin Gene Sequence to Activate Drugs Only within Tumor Cells. Blood. 114: 1851-1851. DOI: 10.1182/Blood.V114.22.1851.1851 |
0.494 |
|
| 2009 |
Sanchez E, Li M, Steinberg JA, Wang CS, Shen J, Bonavida B, Li Z, Chen H, Berenson JR. Oral Dosing of the Novel Proteasome Inhibitor CEP-18770 Shows Marked Anti-Myeloma Effects in SCID-Hu Models of Multiple Myeloma. Blood. 114: 1840-1840. DOI: 10.1182/Blood.V114.22.1840.1840 |
0.348 |
|
| 2009 |
Sanchez E, Berenson J, Chen H, Li M, Wang C, Berenson A, Li J, Steinberg J, Wang J, Shen J, Li Z, Bonavida B. B206 Characterization of Cancer Stem Cells in Multiple Myeloma Clinical Lymphoma and Myeloma. 9: S112. DOI: 10.1016/S1557-9190(11)70683-7 |
0.319 |
|
| 2008 |
Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leukemia & Lymphoma. 49: 1982-94. PMID 18949621 DOI: 10.1080/10428190802357071 |
0.745 |
|
| 2008 |
Huerta S, Chilka S, Bonavida B. Nitric oxide donors: novel cancer therapeutics (review). International Journal of Oncology. 33: 909-27. PMID 18949354 DOI: 10.3892/Ijo_00000079 |
0.379 |
|
| 2008 |
Huerta-Yepez S, Baay-Guzman GJ, Garcia-Zepeda R, Hernandez-Pando R, Vega MI, Gonzalez-Bonilla C, Bonavida B. 2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. Clinical Immunology (Orlando, Fla.). 129: 313-24. PMID 18793875 DOI: 10.1016/J.Clim.2008.07.023 |
0.303 |
|
| 2008 |
Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR. NF-κB in the pathogenesis and treatment of multiple myeloma Current Opinion in Hematology. 15: 391-399. PMID 18536579 DOI: 10.1097/Moh.0B013E328302C7F4 |
0.321 |
|
| 2008 |
Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D, Yeung K. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 19: 152-7. PMID 18477483 DOI: 10.1016/J.Niox.2008.04.018 |
0.57 |
|
| 2008 |
Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Journal of Immunology (Baltimore, Md. : 1950). 180: 6199-210. PMID 18424742 DOI: 10.4049/Jimmunol.180.9.6199 |
0.773 |
|
| 2008 |
Bilir A, Erguven M, Oktem G, Ozdemir A, Uslu A, Aktas E, Bonavida B. Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. International Journal of Oncology. 32: 829-39. PMID 18360710 DOI: 10.3892/Ijo.32.4.829 |
0.465 |
|
| 2008 |
SancheZ E, Campbell RA, Steinberg JA, Li M, Chen H, Bonavida B, Berenson JR. The Novel Proteasome Inhibitor CEP-18770 Inhibits Myeloma Tumor Growth In Vitro and In Vivo and Enhances the Anti-MM Effects of Melphalan Blood. 112: 843-843. DOI: 10.1182/Blood.V112.11.843.843 |
0.413 |
|
| 2008 |
Luria-Pérez R, Peña-Alonso YR, Hernández-Cueto DD, Maldonado-Valenzuela A, Baay-Guzmán GJ, Diaz-Elizondo G, Lara-Martínez LA, Juárez-Caballero G, Vega MI, Bonavida B, Huerta-Yepez S. HIF-1a Expression and Implication in the Resistance Regulation and Malignancy in Pediatric Lymphomas Non-Hodgkin’s Tissue Arrays Blood. 112: 5308-5308. DOI: 10.1182/Blood.V112.11.5308.5308 |
0.434 |
|
| 2008 |
Paniagua MM, Vega MI, Huerta-Yepez S, Gonzalez B, Suarez V, Baritaki S, Berenson JR, Bonavida B. Mechanism of Obatoclax (GX15-070; Bcl-2 Family Inhibitor)-Induced-Sensitization of B-NHL Cells to TRAIL-Mediated Apoptosis: Inhibition of the NF-κB Survival Pathway and the DR5 Transcription Repressor Yin Yang1 (YY1) Blood. 112: 4976-4976. DOI: 10.1182/Blood.V112.11.4976.4976 |
0.583 |
|
| 2008 |
Vega MI, Paniagua MM, Huerta-Yepez S, Suzuki E, Umezawa K, Yeung K, Libra M, Baritaki S, Palladino MA, Bonavida B. Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP Blood. 112: 4973-4973. DOI: 10.1182/Blood.V112.11.4973.4973 |
0.557 |
|
| 2008 |
Chen H, Li M, Sanchez E, Wang CS, Berenson AM, Li J, Steinberg JA, Wang J, Shen J, Li Z, Bonavida B, Berenson JR. Characterization of Cancer Stem Cells in Multiple Myeloma Blood. 112: 495-495. DOI: 10.1182/Blood.V112.11.495.495 |
0.455 |
|
| 2008 |
Suzuki E, Umezawa K, Helguera G, Daniels TR, Schiller G, Berenson JR, Penichet ML, Bonavida B. Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis Blood. 112: 4473-4473. DOI: 10.1182/Blood.V112.11.4473.4473 |
0.528 |
|
| 2008 |
Baritaki S, Rodriguez J, Helguera G, Martinez-Paniagua M, Vega M, Huerta-Yepez S, Jazirehi A, Spandidos D, Penichet ML, Bonavida B. Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance Blood. 112: 3770-3770. DOI: 10.1182/Blood.V112.11.3770.3770 |
0.732 |
|
| 2008 |
Martinez-Paniagua M, Vega MI, Huerta-Yepez S, Baritaki S, Berenson JR, Hariharan H, Bonavida B. Galiximab (anti-CD80 mAb)-Induced Cell Triggering Results in the Inhibition of Constitutive NF-Kb Activity in Raji: Contrasting Roles of Snail and RKIP in the Regulation of Drug/Immune Resistance Blood. 112: 3623-3623. DOI: 10.1182/Blood.V112.11.3623.3623 |
0.569 |
|
| 2008 |
Libra M, Castellano G, Baritaki S, Huerta-Yepez S, Ligresti G, Militello L, Malaponte G, Stivala F, Canevari S, Bonavida B. Expression, Role in Transformation and Prognostic Significance of the Transcription Factor Yin Yang 1 (YY1) in Non-Hodgkin’s Lymphoma: Analyses in NHL Tissues by Experimental and Bioinformatic Approaches Blood. 112: 2827-2827. DOI: 10.1182/Blood.V112.11.2827.2827 |
0.459 |
|
| 2008 |
Sanchez E, Steinberg JA, Li M, Chen H, Bonavida B, Deitcher SR, Hagey AE, Berenson JR. In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Multiple Myeloma Blood. 112: 2760-2760. DOI: 10.1182/Blood.V112.11.2760.2760 |
0.37 |
|
| 2008 |
Huerta-Yepez S, Rivera-Pazos C, Libra M, Baritaki S, Chen H, Berenson JR, Bonavida B. Prognostic Significance of Both the Cytoplasmic and Nuclear Overexpression of Yin-Yang 1 (YY1) among Patients with Multiple Myeloma (MM) Blood. 112: 2730-2730. DOI: 10.1182/Blood.V112.11.2730.2730 |
0.492 |
|
| 2008 |
Baritaki S, Huerta-Yepez S, de Lourdes Cabera-Muñoz M, Rivera-Pazos C, Yeung K, Penichet ML, Chen H, Berenson JR, Bonavida B. Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM): RKIP Overexpression and RKIP Phosphorylation Is Common in MM Tumor Cells Blood. 112: 2729-2729. DOI: 10.1182/Blood.V112.11.2729.2729 |
0.48 |
|
| 2008 |
Li Z, Shalitin D, Shen J, Share M, Li M, Wang CS, Sanchez E, Steinberg JA, Chen H, Bonavida B, Berenson JR. A Novel Targeted Therapeutic Approach to Multiple Myeloma Using Tumor Specific Anti-Sense RNA Sequences Blood. 112: 2727-2727. DOI: 10.1182/Blood.V112.11.2727.2727 |
0.432 |
|
| 2008 |
Vega MI, Martinez-Paniagua M, Huerta-Yepez S, Bonavida B. Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and Immune-Sensitization Blood. 112: 2613-2613. DOI: 10.1182/Blood.V112.11.2613.2613 |
0.49 |
|
| 2008 |
Baritaki S, Chapman A, Wu K, Yeung K, Spandidos D, Berenson JR, Palladino MA, Bonavida B. The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase Inhibitor Protein RKIP) in B-NHL via Inhibition of the Transcription Repressor Snail: Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis Blood. 112: 2611-2611. DOI: 10.1182/Blood.V112.11.2611.2611 |
0.583 |
|
| 2008 |
Chen H, Wang CS, Li M, Sanchez E, Li J, Berenson AM, Steinberg JA, Chen H, Shen J, Li Z, Bonavida B, Berenson JR. A Novel Method for Screening Anti-Angiogenic Compounds: The Chorionicallantoic Membrane (CAM)/Feather Bud (FB) Assay. Blood. 112: 1896-1896. DOI: 10.1182/Blood.V112.11.1896.1896 |
0.394 |
|
| 2008 |
Vega MI, Martinez-Paniagua M, Huerta-Yepez S, Kam Y, Baritaki S, Bonavida B. Molecular Mechanism by Which Rituximab Sensitizes B-NHL Cells to TRAIL Apoptosis: Induction of RKIP and DR5 Expression Via Inhibition of NF-Kb, Snail, and YY1. Blood. 112: 1596-1596. DOI: 10.1182/Blood.V112.11.1596.1596 |
0.565 |
|
| 2008 |
Bonavida B. The rituximab-PKCζ/Raf-1/mTOR connection Blood. 111: 5-6. DOI: 10.1182/Blood-2007-09-113399 |
0.449 |
|
| 2007 |
Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H, Horvath S, Chia D, Goodglick L, Bonavida B. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6056-63. PMID 17947468 DOI: 10.1158/1078-0432.Ccr-07-0960 |
0.393 |
|
| 2007 |
Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. Journal of Immunology (Baltimore, Md. : 1950). 179: 5441-53. PMID 17911631 DOI: 10.4049/Jimmunol.179.8.5441 |
0.555 |
|
| 2007 |
Lee JY, Huerta-Yepez S, Vega M, Baritaki S, Spandidos DA, Bonavida B. The NO TRAIL to YES TRAIL in cancer therapy (review). International Journal of Oncology. 31: 685-91. PMID 17786298 DOI: 10.3892/Ijo.31.4.685 |
0.5 |
|
| 2007 |
Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Huerta-Yepez S, Lin J, Chen D, Bonavida B, Livingston EH. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. The Journal of Surgical Research. 142: 184-94. PMID 17603079 DOI: 10.1016/J.Jss.2006.12.551 |
0.465 |
|
| 2007 |
Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson JR. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. British Journal of Haematology. 138: 467-78. PMID 17587338 DOI: 10.1111/J.1365-2141.2007.06675.X |
0.413 |
|
| 2007 |
Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene. 26: 3629-36. PMID 17530016 DOI: 10.1038/Sj.Onc.1210365 |
0.563 |
|
| 2007 |
Baritaki S, Apostolakis S, Kanellou P, Dimanche-Boitrel MT, Spandidos DA, Bonavida B. Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. Advances in Cancer Research. 98: 149-90. PMID 17433910 DOI: 10.1016/S0065-230X(06)98005-1 |
0.443 |
|
| 2007 |
Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Molecular Cancer Therapeutics. 6: 1387-99. PMID 17431117 DOI: 10.1158/1535-7163.Mct-06-0521 |
0.565 |
|
| 2007 |
Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene. 26: 6184-93. PMID 17420722 DOI: 10.1038/sj.onc.1210448 |
0.476 |
|
| 2007 |
Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B, et al. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood. 110: 287-95. PMID 17369488 DOI: 10.1182/Blood-2006-08-042374 |
0.44 |
|
| 2007 |
Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Nonomura N, Bonavida B, et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. International Journal of Oncology. 30: 919-25. PMID 17332931 DOI: 10.3892/Ijo.30.4.919 |
0.442 |
|
| 2007 |
Katsman A, Umezawa K, Bonavida B. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 10: 1-12. PMID 17306602 DOI: 10.1016/J.Drup.2007.01.002 |
0.539 |
|
| 2007 |
Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Research. 67: 1270-81. PMID 17283164 DOI: 10.1158/0008-5472.CAN-06-2184 |
0.736 |
|
| 2007 |
Baritaki S, Yeung K, Chatterjee D, Palladino M, Bonavida B. Induction of Raf-1 Kinase Inhibitory Protein (RKIP) by the Proteasome Inhibitor NPI-0052 and Reversal of B-NHL Resistance to Apoptosis. Blood. 110: 809-809. DOI: 10.1182/Blood.V110.11.809.809 |
0.574 |
|
| 2007 |
Baritaki S, Huerta-Yepez S, Yeung K, Penichet M, Chen H, Shalitin D, Berenson J, Bonavida B. Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM) Compared to Other Tumor Types: Overexpression of RKIP and a Phosphorylated RKIP Is Common in MM Tumor Cells. Blood. 110: 4852-4852. DOI: 10.1182/Blood.V110.11.4852.4852 |
0.486 |
|
| 2007 |
Martinez-Miguel B, Martinez-Paniagua MA, Huerta-Yepez S, Hernandez-Pando R, Gonzalez-Bonilla CR, Bonavida B, Vega MI. Cytotoxicity of Genetically Engineered Fusion Protein with CD154 Peptide Mimetic (OmpC-CD154p) on B-NHL Cell Lines. Blood. 110: 4525-4525. DOI: 10.1182/Blood.V110.11.4525.4525 |
0.439 |
|
| 2007 |
Ortiz-Sanchez E, Daniels TR, Helguera G, Martinez-Maza O, Bonavida B, Penichet ML. The Role of Iron in the Cytotoxicity Induced in Hematopoietic Malignant Cell Lines by an Anti-Transferrin Receptor IgG3-Avidin Fusion Protein and Gambogic Acid. Blood. 110: 4204-4204. DOI: 10.1182/Blood.V110.11.4204.4204 |
0.433 |
|
| 2007 |
Chen H, Wang CS, Li J, Campbell RA, Li M, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S, Chang Y, Bonavida B, Deuel TF, Berenson JR. Zoledronic Acid Suppresses Vasculogenesis: A New Effect of Bisphosphonates. Blood. 110: 3913-3913. DOI: 10.1182/Blood.V110.11.3913.3913 |
0.382 |
|
| 2007 |
Baritaki S, Suzuki E, Vega M, Ho S, Hariharan K, Bonavida B. Galiximab Sensitizes Malignant Human B Cell Lines to Apoptosis by Chemotherapeutic Drugs. Blood. 110: 3591-3591. DOI: 10.1182/Blood.V110.11.3591.3591 |
0.56 |
|
| 2007 |
Chen H, Li M, Li J, Campbell RA, Wang CS, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S, Bonavida B, Berenson JR. Blockage of TRAF6 Signaling Inhibits Osteoclast Formation and Tumor Cell through Blocking the NF-kB and JNK Pathways in Multiple Myeloma. Blood. 110: 2511-2511. DOI: 10.1182/Blood.V110.11.2511.2511 |
0.496 |
|
| 2007 |
Vega MI, Huerta-Yepez S, Baritaki S, Martinez-Paniagua MA, Gonzalez-Bonilla CR, Bonavida B. Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab). Blood. 110: 2350-2350. DOI: 10.1182/Blood.V110.11.2350.2350 |
0.53 |
|
| 2007 |
Chen H, Li M, Campbell R, Wang CS, Li J, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S, Chang Y, Bonavida B, Deuel TF, Berenson JR. Wnt/β-Catenin Signaling Is Essential for the Transdifferentiation of Monocytes into Endothelial Cells by mCSF and Pleiotrophin. Blood. 110: 1512-1512. DOI: 10.1182/Blood.V110.11.1512.1512 |
0.428 |
|
| 2007 |
Martinez-Paniagua MA, Vega MI, Huerta-Yepez S, Martinez-Miguel B, Hernandez-Pando R, Gonzalez-Bonilla CR, Bonavida B. Direct and Enhanced Cytotoxicity of the Bcl-2 Family Inhibitor GX15-070 on Rituximab-Sensitive and Rituximab-Resistant B-NHL Clones. Blood. 110: 1402-1402. DOI: 10.1182/Blood.V110.11.1402.1402 |
0.555 |
|
| 2007 |
Vega M, Huerta-Yepez S, Balis V, Baritaki S, Yeung K, Spandidos D, Bonavida B. C35. Nitric oxide mimics rituximab (chimeric anti-CD20 mAb)-induced chemo/immuno-sensitization of resistant B-non Hodgkin’s lymphoma Nitric Oxide. 17: 28. DOI: 10.1016/J.Niox.2007.09.080 |
0.374 |
|
| 2007 |
Huerta-Yepez S, Balis V, Hernandez-Cueto A, Huerta S, Munõz-Hernandez O, Vega M, Yeung K, Waterman B, Baritaki S, Spandidos D, Bonavida B. C15. Therapeutic preclinical application of NO donor (e.g. DETANONOate) and CDDP in prostate tumor xenograft regression: molecular mechanism of synergy achieved in apoptosis Nitric Oxide. 17: 23. DOI: 10.1016/J.Niox.2007.09.060 |
0.355 |
|
| 2007 |
Baritaki S, Yeung K, Chatterjee D, Huerta-Yepez S, Spandidos D, Bonavida B. B1. Nitric oxide induces RKIP expression and sensitizes tumor cells to TRAIL-mediated apoptosis via inhibition of both NF-κB and YY1 and upregulation of DR5 Nitric Oxide. 17: 16. DOI: 10.1016/J.Niox.2007.09.034 |
0.498 |
|
| 2007 |
Bonavida B, Garban H, Huerta-Yepez S, Vega M, Huerta S, Baritaki S. A19. Chemo and immuno-sensitizing activities of nitric oxide (NO) and reversal of tumor resistance to apoptotic stimuli: Therapeutic implications Nitric Oxide. 17: 13. DOI: 10.1016/J.Niox.2007.09.024 |
0.693 |
|
| 2006 |
Bonavida B. What signals are generated by anti-CD20 antibody therapy? Current Hematologic Malignancy Reports. 1: 205-13. PMID 20425315 DOI: 10.1007/S11899-006-0001-Z |
0.573 |
|
| 2006 |
Bonavida B, Khineche S, Huerta-Yepez S, Garbán H. Therapeutic potential of nitric oxide in cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 9: 157-73. PMID 16822706 DOI: 10.1016/J.Drup.2006.05.003 |
0.767 |
|
| 2006 |
Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 108: 2745-54. PMID 16804109 DOI: 10.1182/Blood-2006-04-020263 |
0.477 |
|
| 2006 |
Huerta-Yepez S, Vega M, Garban H, Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clinical Immunology (Orlando, Fla.). 120: 297-309. PMID 16784892 DOI: 10.1016/J.Clim.2006.03.015 |
0.764 |
|
| 2006 |
Chen H, Li M, Campbell RA, Burkhardt K, Zhu D, Li SG, Lee HJ, Wang C, Zeng Z, Gordon MS, Bonavida B, Berenson JR. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis Oncogene. 25: 6520-6527. PMID 16702955 DOI: 10.1038/Sj.Onc.1209653 |
0.446 |
|
| 2006 |
Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, Popoviciu L, Wang C, Gordon M, Pang S, Bonavida B, Said J, Berenson JR. LAGλ1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma International Journal of Oncology. 28: 1409-1417. PMID 16685443 DOI: 10.3892/Ijo.28.6.1409 |
0.379 |
|
| 2006 |
Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). Journal of Immunology (Baltimore, Md. : 1950). 176: 4757-65. PMID 16585569 DOI: 10.4049/Jimmunol.176.8.4757 |
0.75 |
|
| 2006 |
Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 25: 1125-42. PMID 16314846 DOI: 10.1038/Sj.Onc.1209080 |
0.737 |
|
| 2006 |
Akopyan G, Bonavida B. Understanding tobacco smoke carcinogen NNK and lung tumorigenesis (Review) International Journal of Oncology. 29: 745-752. DOI: 10.3892/Ijo.29.4.745 |
0.316 |
|
| 2006 |
Campbell RA, Sanchez E, Chen H, Turker L, Trac O, Li M, Shalitin D, Gordon MS, Pang S, Bonavida B, Said J, Plowman GD, Fuh G, Berenson JR. Anti-VEGF Antibody Treatment Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma. Blood. 108: 846-846. DOI: 10.1182/Blood.V108.11.846.846 |
0.345 |
|
| 2006 |
Baritaki S, Huerta-Yepez S, Katsman A, Yeung KC, Chatterjee D, Chen H, Berenson J, Bonavida B. Over Expression of YY1 and RKIP in Multiple Myeloma (Cell Lines and MM Tissues). Blood. 108: 5035-5035. DOI: 10.1182/Blood.V108.11.5035.5035 |
0.486 |
|
| 2006 |
Huerta-Yepez S, Vega MI, Baritaki S, Suzuki E, La Vallee T, Bonavida B. 2-Methoxyestradiol Sensitizes B-NHL Cells to TRAIL-Mediated Apoptosis Via Inhibition of HIF-1α, NF-κ B, YY1 and Induction of DR5 Expression. Blood. 108: 4642-4642. DOI: 10.1182/Blood.V108.11.4642.4642 |
0.535 |
|
| 2006 |
Baritaki S, Katsman A, Huerta-Yepez S, Yeung KC, Berenson J, Bonavida B. Nitric Oxide Sensitizes B-NHL Cells to TRAIL-Mediated Apoptosis through Induction of RKIP, Inhibition of YY1 and Upregulation of DR5. Blood. 108: 4604-4604. DOI: 10.1182/Blood.V108.11.4604.4604 |
0.591 |
|
| 2006 |
Gordon MS, Lee HJ, Campbell RA, Drucker CB, Katz M, Leuchter RK, Bonavida B, Berenson JR. Pleiotrophin Promotes Myeloma Proliferation through the Activation of Known and Novel Receptors. Blood. 108: 4354-4354. DOI: 10.1182/Blood.V108.11.4354.4354 |
0.506 |
|
| 2006 |
Campbell RA, Gordon MS, Sanchez E, Chen H, Turker L, Trac O, Li M, Pang S, Bonavida B, Said J, Drachman JG, Berenson JR. The Humanized Anti-CD40 Antibody SGN-40 Inhibits Tumor Growth in LAGκ-1A, a CD40+ Mouse Model of Human Multiple Myeloma. Blood. 108: 3506-3506. DOI: 10.1182/Blood.V108.11.3506.3506 |
0.39 |
|
| 2006 |
Campbell RA, Sanchez E, Chen H, Turker L, Trac O, Li M, Shalitin D, Gordon MS, Pang S, Bonavida B, Said J, Jeffers M, Qian X, Lichenstein HS, Berenson JR. Effects of a Novel Histone Deacetylase Inhibitor, PXD101, When Used as Monotherapy or in Combination with Bortezomib on Tumor Growth in Mouse Models of Human Multiple Myeloma. Blood. 108: 3483-3483. DOI: 10.1182/Blood.V108.11.3483.3483 |
0.469 |
|
| 2006 |
Campbell RA, Sanchez E, Chen H, Turker L, Li M, Trac O, Shalitin D, Gordon MS, Pang S, Bonavida B, Said J, Wallner B, Gale RP, Berenson JR. ZIO-101, a Novel Organic Arsenic, Inhibits Human Myeloma Cell Growth in a SCID-hu Model. Blood. 108: 3462-3462. DOI: 10.1182/Blood.V108.11.3462.3462 |
0.367 |
|
| 2006 |
Campbell RA, Sanchez E, Chen H, Turker L, Trac O, Li M, Shalitin D, Gordon MS, Pang S, Bonavida B, Said J, Berenson RJ, Berenson JR. PK11195, a Ligand of the Peripheral Benzodiazepine Receptor, Inhibits Myeloma Cell Growth In Vitro and Chemosensitizes Myeloma Cells In Vivo in SCID-hu Models of Human Multiple Myeloma. Blood. 108: 3459-3459. DOI: 10.1182/Blood.V108.11.3459.3459 |
0.432 |
|
| 2006 |
Chen H, Li M, Campbell RA, Gordon MS, Shalitin D, Wang CS, Berenson AM, Li J, Drucker CB, Bonavida B, Berenson JR. Blocking TRAF6 Function Domain by TRAF6 Dominant Negative (TRAF6dn) for Inhibition of Multiple Myeloma Cell Proliferative and Increase of Apoptosis through Regulation of NF-κB and JNK Pathways. Blood. 108: 3434-3434. DOI: 10.1182/Blood.V108.11.3434.3434 |
0.475 |
|
| 2006 |
Suzuki E, Huerta-Yepez S, Baritaki S, Palladino M, Bonavida B. Induction of RKIP and Inhibition of the Transcription Repressor YY1 in B-NHL by the Novel Proteasome Inhibitor NPI-0052 and Sensitization to TRAIL-Induced Apoptosis. Blood. 108: 2391-2391. DOI: 10.1182/Blood.V108.11.2391.2391 |
0.614 |
|
| 2006 |
Vega MI, Huerta-Yepez S, Baritaki S, Bonilla-Gonzalez C, Bonavida B. Rituximab-Mediated Sensitization of B-NHL Cells Lines to TRAIL-Induced Apoptosis: Involvement of YY1 Suppression and DR5 Upregulation. Blood. 108: 2387-2387. DOI: 10.1182/Blood.V108.11.2387.2387 |
0.59 |
|
| 2006 |
Suzuki E, Chen H, Baritaki S, Vega MI, Gordon M, Schiller GJ, Berenson J, Bonavida B. Rituximab-Mediated Upregulation of PTEN Expression and Inhibition of Both the PI3K/AKT Pathway and Pleitrophin (PTN) Expression in B-NHL: Roles in Cell Growth Inhibition and Chemosensitization. Blood. 108: 2374-2374. DOI: 10.1182/Blood.V108.11.2374.2374 |
0.521 |
|
| 2006 |
Vega MI, Huerta-Yepez S, Martinez-Paniagua MA, Bonilla CG, Bonavida B. Rituximab-Mediated Inhibition of the p38 MAPK and NF-κB Survival Pathways In Vitro and Validation in Nude Mice Bearing the Raji B-NHL Tumor. Blood. 108: 2373-2373. DOI: 10.1182/Blood.V108.11.2373.2373 |
0.504 |
|
| 2006 |
Chen H, Campbell RA, Li M, Gordon MS, Shalitin D, Wang CS, Berenson AM, Li J, Wong H, Bonavida B, Berenson JR. Pleiotrophin Is Highly Produced by Myeloma and Breast Cancer and Transdifferentiates Human Monocytes into Endothelial Cells That Are Incorporated into Tumoral Blood Vessels. Blood. 108: 1269-1269. DOI: 10.1182/Blood.V108.11.1269.1269 |
0.438 |
|
| 2006 |
Chen H, Li M, Campbell RA, Gordon MS, Shalitin D, Wang CS, Berenson AM, Li J, Wong H, Wang J, Bonavida B, Berenson JR. Arsenic Trioxide Affects Early Stage Angiogenesis through Inhibition of CD14 Monocyte Transdifferentiation into Endothelial Cells Induced by Pleiotrophin and mCSF. Blood. 108: 1267-1267. DOI: 10.1182/Blood.V108.11.1267.1267 |
0.399 |
|
| 2005 |
Neshat M, Baritaki S, Huerta-Yepez S, Katsman A, Delgado T, Umezawa K, Sakai T, Yeung KC, Chatterjee D, Bonavida B. Sensitization of prostate cancer cells to TRAIL-induced apoptosis by CDDP: Involvement of NF-κB, YY1 and RKIP in upregulation of DR5 expression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3189. PMID 27946004 DOI: 10.1200/Jco.2005.23.16_Suppl.3189 |
0.47 |
|
| 2005 |
Hongo F, Garban H, Huerta-Yepez S, Vega M, Jazirehi AR, Mizutani Y, Miki T, Bonavida B. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochemical and Biophysical Research Communications. 336: 692-701. PMID 16143308 DOI: 10.1016/J.Bbrc.2005.08.150 |
0.835 |
|
| 2005 |
Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene. 24: 8114-27. PMID 16103877 DOI: 10.1038/Sj.Onc.1208954 |
0.845 |
|
| 2005 |
Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. Journal of Immunology (Baltimore, Md. : 1950). 175: 2174-83. PMID 16081784 DOI: 10.4049/Jimmunol.175.4.2174 |
0.767 |
|
| 2005 |
Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L, Bonavida B. Expression of transcription factor Yin Yang 1 in prostate cancer. International Journal of Oncology. 27: 131-41. PMID 15942652 DOI: 10.3892/Ijo.27.1.131 |
0.706 |
|
| 2005 |
Bonavida B, Vega MI. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 8: 27-41. PMID 15939340 DOI: 10.1016/J.Drup.2005.02.004 |
0.524 |
|
| 2005 |
Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 24: 2121-43. PMID 15789036 DOI: 10.1038/Sj.Onc.1208349 |
0.767 |
|
| 2005 |
Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Research. 65: 264-76. PMID 15665303 |
0.716 |
|
| 2005 |
Mizutani Y, Nakanishi H, Yamamoto K, Li YN, Matsubara H, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 448-54. PMID 15572731 DOI: 10.1200/Jco.2005.02.191 |
0.444 |
|
| 2005 |
Suzuki E, Gan X, Umezawa K, Helguera G, Schiller G, Penichet M, Bonavida B. Chemosensitization of CDDP-Resistant Multiple Myeloma Cell Lines Following Treatment with Anti-TfR IgG3-Av. Blood. 106: 5119-5119. DOI: 10.1182/Blood.V106.11.5119.5119 |
0.554 |
|
| 2005 |
Gordon MS, Berenson AM, Drucker CB, Katz M, Lee HJ, Campbell RA, Chen H, Yeh HS, Bonavida B, Said J, Berenson JR. Peripheral Blood Cells from Multiple Myeloma Patients Show Increased Osteoclast and Decreased Osteoblast Gene Expression. Blood. 106: 5098-5098. DOI: 10.1182/Blood.V106.11.5098.5098 |
0.305 |
|
| 2005 |
Neshat MS, Chen H, Gordon MS, Berenson JR, Bonavida B. Differential Presence of Truncated Forms of Transcription Factor Yin Yang 1 (YY1) in Bone Marrow of Multiple Myeloma Patients. Blood. 106: 5083-5083. DOI: 10.1182/Blood.V106.11.5083.5083 |
0.439 |
|
| 2005 |
Neshat M, Jazirehi AR, Bonavida B. Chemosensitization of Drug-Resistant Ramos B-NHL to Drug-Induced Apoptosis: YY1 Expression Is Decreased in Response to Cytoskeletal-Interacting Drugs. Blood. 106: 4806-4806. DOI: 10.1182/Blood.V106.11.4806.4806 |
0.73 |
|
| 2005 |
Chen H, Campbell RA, Wang C, Li M, Lee HJ, Yeh HS, Gui D, Gordon MS, Said J, Bonavida B, Berenson JR. Transdifferentiation of Monocytes into Endothelial Cells by Pleiotrophin. Blood. 106: 391-391. DOI: 10.1182/Blood.V106.11.391.391 |
0.401 |
|
| 2005 |
Yeh HS, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Jin H, Gordon MS, Bonavida B, Berenson JR. Serum Pleiotrophin Is a New Multiple Myeloma Tumor Marker That Also Predicts Clinical Status. Blood. 106: 3417-3417. DOI: 10.1182/Blood.V106.11.3417.3417 |
0.326 |
|
| 2005 |
Huerta-Yepez S, Baritaki S, Hernandez-Cuecto A, Anguino-Hernandez Y, Neshat M, Chen H, Campbell RA, Gordon MS, Berenson JR, Bonavida B. Overexpression and Preferential Nuclear Translocation of the Transcription Factor Yin Yang 1 (YY1) in Human Bone Marrow-Derived Multiple Myeloma. Blood. 106: 3394-3394. DOI: 10.1182/Blood.V106.11.3394.3394 |
0.48 |
|
| 2005 |
Suzuki E, Jazirehi AR, Bonavida B. Rituximab-Mediated Inhibition of the PI3K-Akt Survival Signaling Pathway in B-NHL Cell Lines Leading to Downregulation of Bclxl Expression and Chemosensitization. Blood. 106: 2830-2830. DOI: 10.1182/Blood.V106.11.2830.2830 |
0.769 |
|
| 2005 |
Gordon MS, Lee HJ, Campbell RA, Chen H, Bonavida B, Berenson JR. Identification of Novel Receptors on Myeloma Cells and Monocytes That Contribute to Myeloma Tumor Proliferation and Angiogenesis. Blood. 106: 2507-2507. DOI: 10.1182/Blood.V106.11.2507.2507 |
0.512 |
|
| 2005 |
Chen H, Campbell RA, Gordon MS, Manyak SJ, Wang C, Li M, Lee HJ, Wei J, Yeh HS, Bonavida B, Berenson JR. Circulating Tie2-Expressing Cells Are Increased in Multiple Myeloma Patients, Correlate with Serum Pleiotrophin Levels and May Develop from This Myeloma Angiogenic and Growth Factor. Blood. 106: 2494-2494. DOI: 10.1182/Blood.V106.11.2494.2494 |
0.389 |
|
| 2005 |
Huerta-Yepez S, Vega M, Gui D, Said J, Bonavida B. Analysis of YY1 and XIAP Expression, Proteins That Regulate Resistance, in AIDS-NHL Tissue Arrays. Blood. 106: 1933-1933. DOI: 10.1182/Blood.V106.11.1933.1933 |
0.567 |
|
| 2005 |
Suzuki E, Jazirehi A, Palladino M, Bonavida B. Chemosensitization of Drug and Rituximab-Resistant Daudi B-NHL Clones to Drug-Induced Apoptosis by the Proteasome Inhibitor NPI-0052. Blood. 106: 1521-1521. DOI: 10.1182/Blood.V106.11.1521.1521 |
0.783 |
|
| 2005 |
Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Regulation of Chemoresistance and Immune Resistance of B-NHL Cell Lines by Overexpression of YY1 and Bcl-xL, Respectively: Reversal of Resistance by Rituximab. Blood. 106: 1517-1517. DOI: 10.1182/Blood.V106.11.1517.1517 |
0.78 |
|
| 2005 |
Vega M, Jazirehi A, Bonavida B. Reversal of Rituximab-Resistant AIDS-B-NHL Clone to Chemotherapeutic Drug-Induced Apoptosis by Bortezomib and DHMEQ. Blood. 106: 1516-1516. DOI: 10.1182/Blood.V106.11.1516.1516 |
0.776 |
|
| 2005 |
Jazirehi AR, Bonavida B. Sensitization of Rituximab-Sensitive and Rituximab-Resistant B-NHL Cell Lines/Clones to TRAIL-Induced Apoptosis by Bortezomib and NF-κB Inhibitors. Blood. 106: 1514-1514. DOI: 10.1182/Blood.V106.11.1514.1514 |
0.785 |
|
| 2005 |
Campbell RA, Chen H, Lee HJ, Yeh HS, Gordon MS, Bonavida B, Pang S, Said J, Berenson JR. Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth In Vitro and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM. Blood. 106: 114-114. DOI: 10.1182/Blood.V106.11.114.114 |
0.433 |
|
| 2005 |
Chen H, Zhu D, Campbell R, Pan-James C, Wang C, Gordon M, Bonavida B, Berenson J. Pleiotrophin is a key switch of human monocytes and bone marrow stem cells into endotherlial-like cells for angiogenesis in tumor growth Biology of Blood and Marrow Transplantation. 11: 85-86. DOI: 10.1016/J.Bbmt.2004.12.252 |
0.332 |
|
| 2004 |
Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Research. 64: 7117-26. PMID 15466208 DOI: 10.1158/0008-5472.Can-03-3500 |
0.743 |
|
| 2004 |
Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer. 101: 1794-802. PMID 15386310 DOI: 10.1002/Cncr.20550 |
0.473 |
|
| 2004 |
Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Advances in Cancer Research. 91: 169-200. PMID 15327891 DOI: 10.1016/S0065-230X(04)91005-6 |
0.772 |
|
| 2004 |
Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein MC, Belperio J, Strieter RM, Bonavida B, Ardehali A. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. Journal of Immunology (Baltimore, Md. : 1950). 172: 7417-24. PMID 15187119 DOI: 10.4049/Jimmunol.172.12.7417 |
0.317 |
|
| 2004 |
Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 23: 3530-40. PMID 15077178 DOI: 10.1038/Sj.Onc.1207336 |
0.813 |
|
| 2004 |
Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 23: 4993-5003. PMID 15048072 DOI: 10.1038/Sj.Onc.1207655 |
0.835 |
|
| 2004 |
Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics. 3: 71-84. PMID 14749477 |
0.74 |
|
| 2004 |
Jazirehi AR, Umezawa K, Bonavida B. Sensitization of Rituximab-Resistant Ramos RR1 and Daudi RR1 Clones to Various Chemotherapeutic Drugs by a Novel Nuclear Factor-κB Activation Inhibitor. Blood. 104: 83-83. DOI: 10.1182/Blood.V104.11.83.83 |
0.761 |
|
| 2004 |
Jazirehi AR, Bonavida B. Cellular and Molecular Characterization of Rituximab-Resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) Clones: Development of Cross-Resistance to Cytotoxic Stimuli. Blood. 104: 3410-3410. DOI: 10.1182/Blood.V104.11.3410.3410 |
0.765 |
|
| 2004 |
Vega MI, Huerta-Yepez S, Chinn P, Hariharan H, Hanna N, Bonavida B. Rituximab-Mediated Molecular Cell Signaling Via CD20 in B-NHL Cell Lines: Autonomy from Cross-Linking with Tumor FcRs. Blood. 104: 3404-3404. DOI: 10.1182/Blood.V104.11.3404.3404 |
0.514 |
|
| 2004 |
Chen H, Campbell RA, Zhu D, Li SG, James CP, Santos J, Wang CS, Bonavida B, Berenson JR. Inhibition of Multiple Myeloma Cell Proliferation and Increase of Apoptosis through Regulation of the NF-κB and JNK Pathways by Silencing TRAF6 C-Domain mRNA. Blood. 104: 3355-3355. DOI: 10.1182/Blood.V104.11.3355.3355 |
0.424 |
|
| 2004 |
Chen H, Zhu D, Campbell RA, James CP, Li SG, Santos J, Wang CS, Bonavida B, Berenson JR. Pleitrophin Is Highly Expressed by Myeloma Cells, Elevated in the Serum of Myeloma Patients, and Is a New Autocrine Growth Factor for This B Cell Malignancy. Blood. 104: 3349-3349. DOI: 10.1182/Blood.V104.11.3349.3349 |
0.418 |
|
| 2004 |
Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab-Mediated Inhibition of the Constitutive NIK/IKK/IκB/NF-κB Signaling Pathway in Non-Hodgkin’s Lymphoma (NHL) B-Cell Lines: Role in Chemo-Sensitization. Blood. 104: 288-288. DOI: 10.1182/Blood.V104.11.288.288 |
0.766 |
|
| 2004 |
Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab-Mediated Inhibition of the Transcription Repressor Yin-Yang 1 (YY1) in NHL B Cell Lines: Upregulation of Fas Expression and Sensitization to Fas-Induced Apoptosis. Blood. 104: 287-287. DOI: 10.1182/Blood.V104.11.287.287 |
0.835 |
|
| 2004 |
Campbell RA, Chen H, Zhu D, Santos JC, Bonavida B, Pang S, Said J, Berenson JR. Ascorbic Acid Overcomes Drug Resistance in Myeloma and Significantly Increases the Anti-Myeloma Effects of both Arsenic Trioxide and Melphalan in Vitro and in Vivo. Blood. 104: 2470-2470. DOI: 10.1182/Blood.V104.11.2470.2470 |
0.435 |
|
| 2004 |
Campbell RA, Chen H, Zhu D, Santos JC, Bonavida B, Pang S, Said J, Berenson JR. Arsenic Trioxide Shows Synergistic Anti-Myeloma Effects When Combined with Bortezomib and Melphalan In Vitro and Helps Overcome Resistance of Multiple Myeloma Cells to These Treatments in Vivo. Blood. 104: 2467-2467. DOI: 10.1182/Blood.V104.11.2467.2467 |
0.401 |
|
| 2004 |
Chen H, Zhu D, Campbell RA, James CP, Wang CS, Santos J, Bonavida B, Berenson JR. Pleitrophin Alone Induces Transdifferentiation of Human Monocytes and Bone Marrow Stem Cells into Endothelial Cells. Blood. 104: 1472-1472. DOI: 10.1182/Blood.V104.11.1472.1472 |
0.409 |
|
| 2003 |
Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics. 2: 1183-93. PMID 14617792 |
0.741 |
|
| 2003 |
Hansch C, Jazirehi A, Mekapati SB, Garg R, Bonavida B. QSAR of apoptosis induction in various cancer cells. Bioorganic & Medicinal Chemistry. 11: 3015-9. PMID 12788369 DOI: 10.1016/S0968-0896(03)00184-6 |
0.719 |
|
| 2003 |
Gan XH, Zhang L, Heber D, Bonavida B. Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. International Immunopharmacology. 3: 811-24. PMID 12781698 DOI: 10.1016/S1567-5769(02)00298-9 |
0.365 |
|
| 2003 |
Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Current Medicinal Chemistry. Anti-Cancer Agents. 3: 77-93. PMID 12678904 |
0.816 |
|
| 2003 |
Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. International Journal of Oncology. 22: 663-70. PMID 12579322 |
0.718 |
|
| 2003 |
Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 316-26. PMID 12538484 |
0.832 |
|
| 2003 |
Hansch C, Bonavida B, Jazirehi AR, Cohen JJ, Milliron C, Kurup A. Quantitative structure-activity relationships of phenolic compounds causing apoptosis. Bioorganic & Medicinal Chemistry. 11: 617-20. PMID 12538027 DOI: 10.1016/S0968-0896(02)00326-7 |
0.667 |
|
| 2003 |
Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. International Journal of Oncology. 22: 431-7. PMID 12527945 DOI: 10.3892/Ijo.22.2.431 |
0.507 |
|
| 2003 |
Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis International Journal of Oncology. 22: 663-670. DOI: 10.3892/Ijo.22.3.663 |
0.496 |
|
| 2002 |
Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biotherapy & Radiopharmaceuticals. 17: 621-30. PMID 12537665 DOI: 10.1089/108497802320970226 |
0.728 |
|
| 2002 |
Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Molecular Cancer Therapeutics. 1: 1051-8. PMID 12481428 |
0.819 |
|
| 2002 |
Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biotherapy & Radiopharmaceuticals. 17: 563-7. PMID 12470426 DOI: 10.1089/108497802760804790 |
0.332 |
|
| 2002 |
Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. The Prostate. 53: 286-99. PMID 12430140 DOI: 10.1002/Pros.10155 |
0.82 |
|
| 2002 |
Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Advances in Cancer Research. 85: 145-74. PMID 12374285 DOI: 10.1016/S0065-230X(02)85005-9 |
0.818 |
|
| 2002 |
Gan X, Zhang L, Solomon GF, Bonavida B. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity. Brain, Behavior, and Immunity. 16: 227-46. PMID 12009684 DOI: 10.1006/Brbi.2000.0615 |
0.416 |
|
| 2002 |
Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 836-45. PMID 11895917 |
0.813 |
|
| 2002 |
Mori S, Murakami-Mori K, Nakamura S, Bonavida B. Actinomycin D-mediated sensitization of AIDS-Kaposi's sarcoma cells to Fas-mediated apoptosis: involvement of the mitochondrion-dependent pathway. International Journal of Oncology. 20: 819-26. PMID 11894131 DOI: 10.3892/Ijo.20.4.819 |
0.461 |
|
| 2002 |
Mizutani Y, Wada H, Yoshida O, Fukushima M, Bonavida B, Kawauchi A, Miki T. Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer. Oncology Reports. 9: 289-92. PMID 11836594 DOI: 10.3892/Or.9.2.289 |
0.311 |
|
| 2002 |
Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. European Journal of Cancer (Oxford, England : 1990). 38: 167-76. PMID 11750847 DOI: 10.1016/S0959-8049(01)00339-2 |
0.536 |
|
| 2002 |
Hansch C, Bonavida B, Jazirehi AR, Cohen JJ, Milliron C, Kurup A. Quantitative structure - Activity relationships of phenolic compounds causing apoptosis Bioorganic and Medicinal Chemistry. 11: 617-620. DOI: 10.1016/S0968-0896(02)00326-7 |
0.61 |
|
| 2001 |
Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 459-71. PMID 11759069 DOI: 10.1097/00002371-200111000-00003 |
0.824 |
|
| 2001 |
Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3874-83. PMID 11751478 |
0.849 |
|
| 2001 |
Keith Bechtel M, Bonavida B. Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecologic Oncology. 82: 127-38. PMID 11426974 DOI: 10.1006/Gyno.2001.6221 |
0.35 |
|
| 2001 |
Garbán HJ, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 167: 75-81. PMID 11418634 DOI: 10.4049/Jimmunol.167.1.75 |
0.71 |
|
| 2001 |
Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. Journal of Immunology (Baltimore, Md. : 1950). 166: 3564-73. PMID 11207317 DOI: 10.4049/Jimmunol.166.5.3564 |
0.467 |
|
| 2001 |
Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B, Miki T. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. The Journal of Urology. 165: 263-70. PMID 11125422 DOI: 10.1097/00005392-200101000-00076 |
0.528 |
|
| 2001 |
Garbán HJ, Bonavida B. Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity. The Journal of Biological Chemistry. 276: 8918-23. PMID 11118442 DOI: 10.1074/Jbc.M008471200 |
0.726 |
|
| 2000 |
Jewett A, Bonavida B. MHC-Class I antigens regulate both the function and the survival of human peripheral blood NK cells: role of endogenously secreted TNF-alpha. Clinical Immunology (Orlando, Fla.). 96: 19-28. PMID 10873424 DOI: 10.1006/Clim.2000.4871 |
0.418 |
|
| 2000 |
Mizutani Y, Okada Y, Yoshida O, Bonavida B. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer. Cancer Biotherapy & Radiopharmaceuticals. 11: 385-91. PMID 10851499 DOI: 10.1089/Cbr.1996.11.385 |
0.453 |
|
| 2000 |
Frost P, Bonavida B. Circumvention of tumor cell escape following specific immunotherapy. Cancer Biotherapy & Radiopharmaceuticals. 15: 141-52. PMID 10803319 DOI: 10.1089/Cbr.2000.15.141 |
0.47 |
|
| 2000 |
Itakura M, Mori S, Park NH, Bonavida B. Both HPV and carcinogen contribute to the development of resistance to apoptosis during oral carcinogenesis. International Journal of Oncology. 16: 591-7. PMID 10675494 DOI: 10.3892/Ijo.16.3.591 |
0.373 |
|
| 1999 |
Van Ophoven A, Ng CP, Patel B, Bonavida B, Belldegrun A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Prostate Cancer and Prostatic Diseases. 2: 227-233. PMID 12497168 DOI: 10.1038/Sj.Pcan.4500373 |
0.797 |
|
| 1999 |
Murakami-Mori K, Mori S, Bonavida B. Molecular pathogenesis of AIDS-associated Kaposi's sarcoma: growth and apoptosis. Advances in Cancer Research. 78: 159-97. PMID 10547670 DOI: 10.1016/S0065-230X(08)61025-8 |
0.456 |
|
| 1999 |
Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, Trevisan C, Taylor J, Detels R, Martínez-Maza O. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clinical Immunology (Orlando, Fla.). 93: 114-23. PMID 10527687 DOI: 10.1006/Clim.1999.4782 |
0.313 |
|
| 1999 |
Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). International Journal of Oncology. 15: 793-802. PMID 10493964 DOI: 10.3892/Ijo.15.4.793 |
0.841 |
|
| 1999 |
Frost PJ, Belldegrun A, Bonavida B. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis. The Prostate. 41: 20-30. PMID 10440872 DOI: 10.1002/(Sici)1097-0045(19990915)41:1<20::Aid-Pros4>3.0.Co;2-W |
0.489 |
|
| 1999 |
Mizutani Y, Wu XX, Yoshida O, Shirasaka T, Bonavida B. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncology Reports. 6: 979-82. PMID 10425290 DOI: 10.3892/OR.6.5.979 |
0.403 |
|
| 1999 |
Garbán HJ, Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecologic Oncology. 73: 257-64. PMID 10329044 DOI: 10.1006/Gyno.1999.5374 |
0.735 |
|
| 1999 |
Mori S, Murakami-Mori K, Bonavida B. Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochemical and Biophysical Research Communications. 257: 609-14. PMID 10198259 DOI: 10.1006/Bbrc.1999.0515 |
0.326 |
|
| 1999 |
Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer. 85: 134-44. PMID 9921985 DOI: 10.1002/(Sici)1097-0142(19990101)85:1<134::Aid-Cncr19>3.0.Co;2-C |
0.437 |
|
| 1999 |
Cavalcanti M, Jewett A, Bonavida B. Irreversible cancer cell-induced functional anergy and apoptosis in resting and activated NK cells. International Journal of Oncology. 14: 361-6. PMID 9917514 DOI: 10.3892/Ijo.14.2.361 |
0.303 |
|
| 1998 |
Mori S, Jewett A, Cavalcanti M, Murakami-Mori K, Nakamura S, Bonavida B. Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. International Journal of Oncology. 12: 1165-70. PMID 9538144 DOI: 10.3892/Ijo.12.5.1165 |
0.339 |
|
| 1998 |
MIZUTANI Y, YOSHIDA O, BONAVIDA B. PROGNOSTIC SIGNIFICANCE OF SOLUBLE FAS IN THE SERUM OF PATIENTS WITH BLADDER CANCER Journal of Urology. 160: 571-576. DOI: 10.1016/S0022-5347(01)62960-4 |
0.386 |
|
| 1998 |
MIZUTANI Y, YOSHIDA O, BONAVIDA B. SENSITIZATION OF HUMAN BLADDER CANCER CELLS TO FAS-MEDIATED CYTOTOXICITY BY CIS-DIAMMINEDICHLOROPLATINUM (II) Journal of Urology. 160: 561-570. DOI: 10.1016/S0022-5347(01)62959-8 |
0.528 |
|
| 1997 |
Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy & Radiopharmaceuticals. 12: 177-86. PMID 10851464 DOI: 10.1089/Cbr.1997.12.177 |
0.831 |
|
| 1997 |
Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 963-72. PMID 9815772 |
0.818 |
|
| 1997 |
Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cellular Immunology. 180: 70-83. PMID 9316641 DOI: 10.1006/Cimm.1997.1169 |
0.826 |
|
| 1997 |
Mori S, Jewett A, Murakami-Mori K, Cavalcanti M, Bonavida B. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunology, Immunotherapy : Cii. 44: 282-90. PMID 9247563 DOI: 10.1007/S002620050384 |
0.426 |
|
| 1997 |
Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer. 79: 1180-9. PMID 9070496 DOI: 10.1002/(Sici)1097-0142(19970315)79:6<1180::Aid-Cncr17>3.0.Co;2-W |
0.493 |
|
| 1997 |
Baek JH, Bertolami CN, Bonavida B, Park NH. Normal human oral keratinocytes are more sensitive to N-methyl-N'-nitro-N-nitrosoguanidine-induced cytotoxicity and apoptosis than HPV-immortalized oral keratinocytes. International Journal of Oncology. 10: 47-51. DOI: 10.3892/Ijo.10.1.47 |
0.425 |
|
| 1996 |
Stewart SA, Feuer G, Jewett A, Lee FV, Bonavida B, Chen IS. HTLV-1 gene expression in adult T-cell leukemia cells elicits an NK cell response in vitro and correlates with cell rejection in SCID mice. Virology. 226: 167-75. PMID 8955035 DOI: 10.1006/Viro.1996.0643 |
0.42 |
|
| 1996 |
Jewett A, Gan XH, Lebow LT, Bonavida B. Differential secretion of TNF-alpha and IFN-gamma by human peripheral blood-derived NK subsets and association with functional maturation. Journal of Clinical Immunology. 16: 46-54. PMID 8926285 DOI: 10.1007/Bf01540972 |
0.311 |
|
| 1996 |
Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis. Gynecologic Oncology. 62: 282-91. PMID 8751562 DOI: 10.1006/Gyno.1996.0228 |
0.542 |
|
| 1996 |
Uslu R, Bonavida B. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum. Cancer. 77: 725-32. PMID 8616765 DOI: 10.1002/(Sici)1097-0142(19960215)77:4<725::Aid-Cncr19>3.0.Co;2-2 |
0.413 |
|
| 1996 |
BONAVIDA B. Chemosensitization of resistant ovarian tumor cells to anti-Fas mediated cytotoxicity and apoptosis. Journal of the Society For Gynecologic Investigation. 3: 194A. DOI: 10.1016/1071-5576(96)82718-3 |
0.442 |
|
| 1995 |
Jewett A, Bonavida B. Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cellular Immunology. 160: 91-7. PMID 7842490 DOI: 10.1016/0008-8749(95)80013-9 |
0.383 |
|
| 1995 |
Gan XH, Robin JP, Huerta JM, Braquet P, Bonavida B. Inhibition of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) secretion but not IL-6 from activated human peripheral blood monocytes by a new synthetic demethylpodophyllotoxin derivative. Journal of Clinical Immunology. 14: 280-8. PMID 7814457 DOI: 10.1007/Bf01540981 |
0.305 |
|
| 1995 |
Mizutani Y, Bonavida B. Pentoxifylline enhances sensitivity of a human ovarian cancer cell line (OVC-8) to TNF-alpha. Biotherapy (Dordrecht, Netherlands). 7: 109-14. PMID 7803190 DOI: 10.1007/Bf01877734 |
0.347 |
|
| 1995 |
Jewett A, Bonavida B. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. Journal of Clinical Immunology. 15: 35-44. PMID 7759599 DOI: 10.1007/Bf01489488 |
0.345 |
|
| 1995 |
Mizutani Y, Bonavida B, Fukumoto M, Yoshida O. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 17: 78-87. PMID 7647959 DOI: 10.1097/00002371-199502000-00002 |
0.466 |
|
| 1995 |
Hu P, Hultin LE, Hultin P, Hausner MA, Hirji K, Jewett A, Bonavida B, Detels R, Giorgi JV. Natural Killer Cell Immunodeficiency in HIV Disease is Manifest by Profoundly Decreased Numbers of CD16 + CD56+ Cells and Expansion of a Population of CD16dim CD56- Cells with Low Lytic Activity Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 10: 331???340. DOI: 10.1097/00042560-199511000-00005 |
0.311 |
|
| 1994 |
Demidem A, Broquet C, Menciahuerta J, Salahuddin S, Lam T, Khan R, Braquet P, Levine A, Bonavida B. Sensitivity of drug-resistant B-cell lines from AIDS-related non-hodgkins-lymphoma to newly synthesized podophyllotoxin derivatives and aza-alkyllysophospholipids - enhanced sensitization by pretreatment with interferon-gamma. International Journal of Oncology. 4: 1203-9. PMID 21567038 DOI: 10.3892/Ijo.4.6.1203 |
0.48 |
|
| 1994 |
Mizutani Y, Bonavida B, Nio Y, Yoshida O. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. The Journal of Urology. 151: 1697-702. PMID 8189599 DOI: 10.1016/S0022-5347(17)35347-8 |
0.325 |
|
| 1994 |
Jewett A, Bonavida B. Pentoxifylline suppresses interleukin-2-mediated activation of immature human natural killer cells by inhibiting endogenous tumor necrosis factor-alpha secretion. Journal of Clinical Immunology. 14: 31-8. PMID 8132735 DOI: 10.1007/Bf01541173 |
0.41 |
|
| 1994 |
Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer. 74: 2546-54. PMID 7923012 DOI: 10.1002/1097-0142(19941101)74:9<2546::Aid-Cncr2820740924>3.0.Co;2-Y |
0.46 |
|
| 1994 |
Jewett A, Bonavida B. Activation of the human immature natural killer cell subset by IL-12 and its regulation by endogenous TNF-alpha and IFN-gamma secretion. Cellular Immunology. 154: 273-86. PMID 7907529 DOI: 10.1006/Cimm.1994.1077 |
0.33 |
|
| 1994 |
Bonavida B, Mencia-Huerta JM. Platelet-Activating Factor and the Cytokine Network in Inflammatory Processes Clinical Reviews in Allergy. 12: 381-395. PMID 7743463 DOI: 10.1007/Bf02802301 |
0.371 |
|
| 1993 |
Safrit JT, Belldegrun A, Bonavida B. Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistance. The Journal of Urology. 149: 1202-8. PMID 8483246 DOI: 10.1016/S0022-5347(17)36348-6 |
0.433 |
|
| 1993 |
Safrit JT, Berek JS, Bonavida B. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype. Gynecologic Oncology. 48: 214-20. PMID 8428693 DOI: 10.1006/Gyno.1993.1036 |
0.384 |
|
| 1993 |
Jewett A, Bonavida B. Pivotal role of endogenous TNF-alpha in the IL-2-driven activation and proliferation of the functionally immature NK free subset. Cellular Immunology. 151: 257-69. PMID 8402935 DOI: 10.1006/Cimm.1993.1236 |
0.358 |
|
| 1993 |
Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer. 72: 809-18. PMID 8334635 DOI: 10.1002/1097-0142(19930801)72:3<809::Aid-Cncr2820720329>3.0.Co;2-5 |
0.439 |
|
| 1993 |
Morimoto H, Principe P, Robin JP, Broquet C, Mencia-Huerta JM, Braquet P, Bonavida B. Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines. Cancer Chemotherapy and Pharmacology. 32: 293-300. PMID 8324871 DOI: 10.1007/BF00686175 |
0.371 |
|
| 1992 |
Safrit JT, Bonavida B. Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins. Cancer Immunology, Immunotherapy : Cii. 34: 321-8. PMID 1540978 DOI: 10.1007/Bf01741553 |
0.506 |
|
| 1991 |
Bonavida B. Immunomodulatory effect of tumor necrosis factor. Biotherapy (Dordrecht, Netherlands). 3: 127-33. PMID 2054253 DOI: 10.1007/Bf02172085 |
0.337 |
|
| 1991 |
Bonavida B, Tsuchitani T, Zighelboim J, Berek J. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells International Journal of Gynecology & Obstetrics. 36: 80-80. DOI: 10.1016/0020-7292(91)90194-A |
0.398 |
|
| 1990 |
Nio Y, Zighelboim J, Berek J, Bonavida B. Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemotherapy and Pharmacology. 26: 1-8. PMID 2322985 DOI: 10.1007/Bf02940285 |
0.459 |
|
| 1990 |
Bonavida B, Tsuchitani T, Zighelboim J, Berek JS. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecologic Oncology. 38: 333-9. PMID 2227544 DOI: 10.1016/0090-8258(90)90068-V |
0.481 |
|
| 1990 |
Lebow LT, Bonavida B. Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets. Proceedings of the National Academy of Sciences of the United States of America. 87: 6063-7. PMID 2143580 DOI: 10.1073/Pnas.87.16.6063 |
0.411 |
|
| 1989 |
Nio Y, Zighelboim J, Berek J, Bonavida B. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Cancer. 64: 434-41. PMID 2736490 DOI: 10.1002/1097-0142(19890715)64:2<434::Aid-Cncr2820640216>3.0.Co;2-Q |
0.445 |
|
| 1989 |
Bonavida B, Mencia-Huerta JM, Braquet P. Effect of platelet-activating factor on monocyte activation and production of tumor necrosis factor. International Archives of Allergy and Applied Immunology. 88: 157-60. PMID 2707879 DOI: 10.1159/000234772 |
0.416 |
|
| 1989 |
Katz JD, Bonavida B. A spontaneous sarcoma dependent on host tumor-specific immune lymphocytes. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 11: 181-5. PMID 2695084 DOI: 10.1002/Bies.950110606 |
0.379 |
|
| 1989 |
Bonavida B, Jewett A. Activation of human peripheral blood-derived monocytes by OK-432 (Streptococcus pyogenes): Augmented cytotoxicity and secretion of TNF and synergy with rIFN-γ1 Cellular Immunology. 123: 373-383. PMID 2507170 DOI: 10.1016/0008-8749(89)90297-9 |
0.381 |
|
| 1988 |
Nio Y, Zighelboim J, Berek JS, Bonavida B. Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432. Cancer Immunology, Immunotherapy : Cii. 27: 246-54. PMID 3180149 DOI: 10.1007/Bf00205447 |
0.44 |
|
| 1988 |
Bonavida B. Mechanism of natural killer cell-mediated cytotoxicity. Annals of the New York Academy of Sciences. 532: 336-40. PMID 3052210 DOI: 10.1111/J.1749-6632.1988.Tb36350.X |
0.407 |
|
| 1988 |
Katz JD, Nishanian P, Mitsuyasu R, Bonavida B. Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells. Journal of Clinical Immunology. 8: 453-8. PMID 2975670 DOI: 10.1007/Bf00916950 |
0.31 |
|
| 1988 |
Katz JD, Ohnishi K, Lebow LT, Bonavida B. The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype. The Journal of Experimental Medicine. 168: 1553-62. PMID 2460577 DOI: 10.1084/Jem.168.5.1553 |
0.38 |
|
| 1987 |
Bonavida B. Molecular mechanism of natural killer cell-mediated cytotoxicity. Advances in Experimental Medicine and Biology. 213: 299-307. PMID 3630830 DOI: 10.1007/978-1-4684-5323-2_29 |
0.403 |
|
| 1987 |
Bonavida B, Katz J, Hoshino T. Mechanism of NK activation by OK-432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells. Cellular Immunology. 102: 126-35. PMID 3492275 DOI: 10.1016/0008-8749(86)90331-X |
0.367 |
|
| 1987 |
Roozemond RC, Urli DC, Wright SC, Graves SS, Bonavida B. Lysis of natural killer-sensitive and -resistant tumor cells by natural killer cytotoxic factors (NKCF)-containing liposomes Immunobiology. 176: 35-46. PMID 3447981 DOI: 10.1016/S0171-2985(87)80098-0 |
0.454 |
|
| 1987 |
Bonavida B, Wright SC. Multistage Model of Natural Killer Cell-Mediated Cytotoxicity Involving Nkcf as Soluble Cytotoxic Mediators Advances in Cancer Research. 49: 169-187. DOI: 10.1016/S0065-230X(08)60797-6 |
0.44 |
|
| 1986 |
Bonavida B, Wright SC. Role of natural killer cytotoxic factors in the mechanism of target-cell killing by natural killer cells Journal of Clinical Immunology. 6: 1-8. PMID 3958135 DOI: 10.1007/Bf00915358 |
0.406 |
|
| 1985 |
Wright SC, Bonavida B. Both NK sensitive and resistant mycoplasma free cell lines stimulate release of NKCF Advances in Experimental Medicine and Biology. 184: 193-201. PMID 4036708 DOI: 10.1007/978-1-4684-8326-0_13 |
0.409 |
|
| 1985 |
Wright SC, Wilbur SM, Bonavida B. Biochemical characterization of natural killer cytotoxic factors. Advances in Experimental Medicine and Biology. 184: 179-91. PMID 3875973 DOI: 10.1007/978-1-4684-8326-0_12 |
0.395 |
|
| 1985 |
Bonavida B, Ostergaard H, Katz J. Mechanism of T-dependent cytotoxicity: role of papain-sensitive non class I MHC target molecules and expression of target antigen for cytotoxicity Advances in Experimental Medicine and Biology. 184: 415-428. PMID 2994412 DOI: 10.1007/978-1-4684-8326-0_28 |
0.4 |
|
| 1984 |
Bradley TP, Bonavida B. Mechanism of cell-mediated cytotoxicity at the single-cell level. VII. Trigger of the lethal hit event is distinct for NK/K and LDCC effector cells as measured in the two-target conjugate assay. Cellular Immunology. 83: 199-207. PMID 6420079 DOI: 10.1016/0008-8749(84)90239-9 |
0.362 |
|
| 1983 |
Bonavida B, Bradley TP, Grimm EA. The single-cell assay in cell-mediated cytotoxicity. Immunology Today. 4: 196-200. PMID 25289827 DOI: 10.1016/0167-5699(83)90081-6 |
0.397 |
|
| 1983 |
Hutchinson IV, Bonavida B. Opsonization of tumor-reactive T cells in SJL/J mice bearing syngeneic tumors. Cancer Immunology, Immunotherapy : Cii. 13: 176-81. PMID 6984656 DOI: 10.1007/Bf00205384 |
0.373 |
|
| 1983 |
Effros R, Fan J, Hiserodt J, Kessler S, Scher I, Bonavida B. Blocking of the induction and expression of immunologically functional T lymphocytes by rat antiactivated T-cell serum. Cellular Immunology. 73: 311-23. PMID 6760991 DOI: 10.1016/0008-8749(82)90458-0 |
0.388 |
|
| 1983 |
Wexler H, Fan J, Hiserodt JC, Bonavida B. Studies on the induction and expression of T-cell-mediated immunity. XIII. Membrane-associated antigens of cytotoxic T lymphocytes involved in cytotoxicity. Cellular Immunology. 75: 214-25. PMID 6600972 DOI: 10.1016/0008-8749(83)90321-0 |
0.323 |
|
| 1983 |
Wright SC, Bonavida B. YAC-1 variant clones selected for resistance to natural killer cytotoxic factors are also resistant to natural killer cell-mediated cytotoxicity Proceedings of the National Academy of Sciences of the United States of America. 80: 1688-1692. PMID 6572932 DOI: 10.1073/Pnas.80.6.1688 |
0.407 |
|
| 1983 |
Kahle R, Hiserodt J, Bonavida B. Characterization of antibody-mediated inhibition of natural killer (NK) cytotoxicity: evidence for blocking of both recognition and lethal hit stages of cytolysis. Cellular Immunology. 80: 97-104. PMID 6409429 DOI: 10.1016/0008-8749(83)90097-7 |
0.356 |
|
| 1983 |
Bonavida B, Bradley TP, Grimm EA. Frequency determination of killer cells by a single-cell cytotoxic assay. Methods in Enzymology. 93: 270-80. PMID 6408349 DOI: 10.1016/S0076-6879(83)93049-5 |
0.382 |
|
| 1983 |
Bonavida B. The SJL/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumor interactions, and regulation of tumor growth. Advances in Cancer Research. 38: 1-22. PMID 6349290 DOI: 10.1016/S0065-230X(08)60185-2 |
0.39 |
|
| 1983 |
Bonavida B, Bradley T, Fan J, Hiserodt J, Effros R, Wexler H. Molecular interactions in T-cell-mediated cytotoxicity. Immunological Reviews. 72: 119-41. PMID 6192075 DOI: 10.1111/J.1600-065X.1983.Tb01075.X |
0.319 |
|
| 1982 |
Kedar E, Ikejiri BL, Sredni B, Bonavida B, Herberman RB. Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cellular Immunology. 69: 305-29. PMID 6980720 DOI: 10.1016/0008-8749(82)90075-2 |
0.436 |
|
| 1982 |
Bonavida B. Molecular interactions in T-cell mediated cytotoxicity: discrimination between the binding and lethal hit stages of cytolysis. Advances in Experimental Medicine and Biology. 146: 575-87. PMID 6980577 DOI: 10.1007/978-1-4684-8959-0_36 |
0.384 |
|
| 1982 |
Wright SC, Bonavida B. Role Of Natural Killer Cytotoxic Factors (Nkcf) In The Mechanism Of Nk Cell Mediated Cytotoxicity Nk Cells and Other Natural Effector Cells. 961-968. DOI: 10.1016/B978-0-12-341360-4.50143-8 |
0.429 |
|
| 1982 |
Bonavida B. Lectin-Dependent Natural Killer Cellular Cytotoxicity In Mice (Nk-Ldcc): A New Subpopulation Of Nk-Like Cytotoxic Cells Nk Cells and Other Natural Effector Cells. 483-491. DOI: 10.1016/B978-0-12-341360-4.50078-0 |
0.391 |
|
| 1982 |
Bradley TP, Bonavida B. Natural Killer Cells Are Distinct From Lectin-Dependent Effector Cells In Man As Determined By The Two-Target Conjugate Single Cell Assay Nk Cells and Other Natural Effector Cells. 145-152. DOI: 10.1016/B978-0-12-341360-4.50028-7 |
0.353 |
|
| 1981 |
Neville ME, Grimm E, Bonavida B. Frequency determination of K cells by a single cell cytotoxic assay. Journal of Immunological Methods. 36: 255-68. PMID 7430654 DOI: 10.1016/0022-1759(80)90131-3 |
0.36 |
|
| 1981 |
Bonavida B, Roman J. Expression of alien histocompatibility antigens on SJL/J tumors detected by cell-mediated and serological analyses Cancer Immunology Immunotherapy. 11. DOI: 10.1007/Bf00199262 |
0.419 |
|
| 1980 |
Bonavida B, Bradley TP. Assessment of cell-mediated cytotoxicity. Immunology Today. 1: 104-9. PMID 25290168 DOI: 10.1016/0167-5699(80)90043-2 |
0.357 |
|
| 1980 |
Roman JM, Bonavida B. Inappropriate alloantigen-like specificities detected on spontaneous and transplantable reticulum cell sarcomas of SJL/J mice. Journal of Immunogenetics. 7: 61-70. PMID 6154750 DOI: 10.1111/J.1744-313X.1980.Tb00708.X |
0.382 |
|
| 1979 |
Grimm E, Price Z, Bonavida B. Studies on the induction and expression of T cell-mediated immunity. VIII. Effector-target junctions and target cell membrane disruption during cytolysis. Cellular Immunology. 46: 77-99. PMID 314849 DOI: 10.1016/0008-8749(79)90247-8 |
0.405 |
|
| 1977 |
Bonavida B, Ikejiri B, Kedar E. Direct estimation of frequency of cytotoxic T lymphocytes by a modified plaque assay. Nature. 263: 769-71. PMID 1086985 DOI: 10.1038/263769A0 |
0.341 |
|
| 1977 |
Bonavida B, Robins A, Saxon A. Lectin-dependent cellular cytotoxicity in man. Transplantation. 23: 261-70. PMID 324045 DOI: 10.1097/00007890-197703000-00009 |
0.418 |
|
| 1977 |
Grimm EA, Bonavida B. Is There A Relationship Between Effector-Target Cell Binding And Cell-Mediated Cytotoxicity? Regulatory Mechanisms in Lymphocyte Activation. 545-547. DOI: 10.1016/B978-0-12-458050-3.50087-4 |
0.429 |
|
| 1977 |
Bonavida B. Concanavalin A Induced Triggering Of Allosensitized Memory Lymphocytes Into Secondary Cytotoxic Lymphocytes Regulatory Mechanisms in Lymphocyte Activation. 316-318. DOI: 10.1016/B978-0-12-458050-3.50022-9 |
0.375 |
|
| 1976 |
Bonavida B, Bradley TP. Studies on the induction and expression of T cell-mediated immunity. V. Lectin-induced nonspecific cell-mediated cytotoxicity by alloimmune lymphocytes. Transplantation. 21: 94-102. PMID 1082670 DOI: 10.1097/00007890-197602000-00002 |
0.46 |
|
| 1975 |
Zighelboim J, Bonavida B, Fahey JL. Heterogenous populations of cytotoxic cells in the peritoneal cavity of BALB/c mice immunized with allogeneic EL4 leukemia cells. Cellular Immunology. 12: 280-9. PMID 4458965 DOI: 10.1016/0008-8749(74)90080-X |
0.441 |
|
| 1975 |
Bonavida B, Zighelboim J. Modulation of the immune response toward allografts in vivo. I. Selective suppression of the development of cell-mediated immunity by soluble alloantigens. Cellular Immunology. 13: 52-65. PMID 4451974 DOI: 10.1016/0008-8749(74)90226-3 |
0.398 |
|
| 1974 |
Zighelboim J, Bonavida B, Fahey JL. Antibody-mediated in vivo suppression of EL4 leukemia in a syngeneic host. Journal of the National Cancer Institute. 52: 879-81. PMID 4826569 DOI: 10.1093/Jnci/52.3.879 |
0.302 |
|
| 1974 |
Kedar E, Ortiz de Landazuri M, Bonavida B, Fahey JL. Cellular immunoadsorbents. An improved technique for specific depletion of cytotoxic (T) lymphoid cells. Journal of Immunological Methods. 5: 97-102. PMID 4546233 DOI: 10.1016/0022-1759(74)90051-9 |
0.312 |
|
| 1974 |
Bonavida B, Kedar E. Transplantation of allogeneic lymphoid cells specifically depleted of graft versus host reactive cells. Nature. 249: 658-9. PMID 4151818 DOI: 10.1038/249658A0 |
0.31 |
|
| Show low-probability matches. |